Use of tellurium-containing compounds for treating warts

1 176876/3

USE OF TELLURIUM-CONTAINING COMPOUNDS IN THE

MANUFACTURE OF A MEDICAMENT FOR TREATING A SKIN OR

MUCOSAL MEMBRANE AILMENT CAUSED BY HPV

FIELD AND BACKGROUND OF THE INVENTION

The present invention relates to novel therapeutic methods and pharmaceutical compositions for treating warts. More particularly, the present invention relates to novel therapeutic methods and pharmaceutical compositions for treating ailments caused by human papilloma viruses.

Human papilloma virus (HPV) infections are common infections of the outer layer of the skin, which affect most persons sometime during their lifetime. To date, over seventy distinct types of HPVs have been already identified. These viruses target the squamous epithelia of the skin and mucosal membranes. Based on this trophism, the different types of HPV have been subdivided into two large categories: cutaneous and mucosal. A third category is sometimes used to designate types of HPV specifically found in people with epidermodysplasia verruciformis (EV). HPV infections typically emerge as skin warts. However, by being spread by auto-innoculation, warts may also occur at any other location in the body. Subjects afflicted with warts may in some cases experience complete regression after several months with or without treatment with recurrence at the same or at different locations.

Skin warts include, for example, common warts (e.g., verruca vulgaris, plantar, palmar and periungal); planar warts (verruca plana); mosaic warts; genital and venereal warts (e.g., condylomata acuminata); butcher's warts; malignant epidermodyspasia verruciformis; advanced intraepithelial dysplasia, mepidermodysplasia verruciformis; cutnaeous warts in immunosuppressed patients; laryngeal papillomas; and oral papilloma. However, clinical manifestations sometimes further include serious infections of the genital mucous membranes, (e.g., advanced intraepithelial dysplasia), which may progress to cervical cancer.

Skin warts, resulting from HPNs are unsightly and irritating, and although the majority of such infections are benign and self-limited, there are subtypes of papilloma virus that are considered pre-malignant in certain clinical settings. Therefore, the removal of emerged skin warts is highly recommended.

Throughout the years a number of therapies have been developed for treating these coetaneous infections. However, most of the presently known methods of WO 2005/069735 PCT/IL2005/000084 2 treating warts'-'are painful, expensive, requiring long treatment periods and/or are ineffective. Most of these methods are initially successful but involve a longer-term treatment failure, exhibited by recurrence, as well as side effects [see, for example, Goldfarbet al.,· Dermatol Clin,1991;9(2):287-96; Hettich, Dermatologica,1984;168 ‘ 5 Supple. 1:36-42; Bunney, M.H., Viral waits: their biology and treatment. New York, NY: Oxford University Press' Inc.,1982; Belisario, Australas J Dermatol, 1951;1:20-30; and Beutneret al. Lancet, 1989;1831-834]. ·

The presently used methods of treating HPV infections typically include the use of locally destructive chemicals or agents, such as salicylic acid, lactic acid, 10' trichloracetic acid, dichloroacetic acid, nitric acid and glacial acetic acid; surgically destructive methods 'such as excision, electrocautery, electrodesiccation, curettage, . blunt dissection and laser vaporization or coagulation; blister-producing methods such as liquid nitrogen"cryotherapy, carbon dioxide.cryotherapy and cantharidin; cellular inhibition, which .uses agents such as podophyllin and podophyllotoxin, '5- . 15 fluorouracil, bleomycin, colchicine, interferon local injections and radiation; altering the cutaneous,enyironoient, which includes agents or techniques such as retinoids, formalin,· glutaraldehyde, aluminum chloride and heat therapy, and immune stimulation methods of treatment, which include dinitrochlorobenzene (DNCB), ' • imiquimod (also known by the trade name Aldara™), interferon systemic injections 20 and vaccination, either autologous or intralesional.

Hence, the presently most common methods of warts treatment can be divided into chemical, surgical and physical methods. The physical methods typically include. destruction of the.infected keratinocytes by cooling (e.g., liquid nitrogen) or heating · (e.g., electrocautery, CO2 laser), and often lead to injury of surrounding tissues, 25 secondary infections and other undesired consequences.

Surgical treatments are typically associated with discomfort,· prolonged ' healing and the. formation of scars and/or keloids, is addition to an inherent risk.. . The chemical:.methods commonly use locally destructive chemicals .and ." typically include.''caustic chemicals that act through nonspecific destructive 30 mechanisms, io 'cause cell death, killing the infected keratinocytes. The keratinocytes are subsequently, desquamated from the skin surface. This non-specific form of • destructive therapy, often causes side effects such as pain, secondary infection, permanent scarring and is oftentimes associated· with recurrence of disease. WO 2005/069735 PCT/EL2005/000084 3

The chemical methods typically involve topical application of the chemical agents as solutions, tinctures, creams, ointments, patches, etc. One of the presently most used chemical' agents for treating warts is salicylic acid, which is typically administered as a patch or a gel. A typical salicylic acid patch contains an amount of 5 salicylic acid in a sticky base or a rubber base. However, the use of salicylic acid in the treatment· of HPV requires repeated administration of the composition for a ' prolonged period of about 4-6 weeks, and is oftentimes unsuccessful.

Hence, most.of the currently available methods focus on the destruction of visible lesions rather than tbe underlying cause of disease, namely the HPV. For 10 example, removal of warts with destructive chemical agents or with physical ablative means do· .not affect viral, particles that may be lurking in normal-appearing areas •surrounding the wart: This is one of the reasons of the high rate of disease recurrence.

The inefficiency of the presently known methods of treating warts have been widely studied and reported in the art. Thus, it was found that using a liquid nitrogen, 15 initial cure is seen in 52-83 '% of patients [Berth-Jones and Hutchinson, Br J Dermatol, 1992;127(3):262-5; Erkens. et al., J.A., Ned Tijdschr Geneeskd, 1991;135(5):171.-4]j· Keefe and Dick. Clin Exp Dermatol, 1990;15(4):260-3], • however, only 57% of the patients remain clear of warts after a median of 19 months [Keefe and Dick. Clin Exp Dermatol,1990;15(4):260-3]. .20 When using, a histofreezer technique the success rate falls to 28 % [Erkens et al., J.A., Ned Tijdschr Geneeskd, 1991; 135(5); 171 -4] and is comparable with placebo •or the success rates'achieved through direct in hypnotic suggestion (27-55 %) [Ewin, D.M., Am J Clin Hypn,1992;35(l):l-10]. Recently, however, individual byproanalytic techniques were shown to cure 80 % of'patients who have failed 25 hypnosis [Robson et al.·, J Am Acad Dermatol, 2000;43(2 Pt 1):275-80].

Since 1970 intralesional bleomycine therapy success rate has remained in the 70 % range [see, for. example, Sobh et al., Acta Derm Venereol

Stockh,1991;7i(l):63-6; .Shelley and Shelley, Arch Dermatol, l991;127(2):234-6;

Hayes and O’Kedfe, J Am Acad Dermatol,1986;15:1002-1006; Mishima and 30 Matunaka, Acta Derm Venereol (Stockh), 1971;52:211-215; and Bennett and Reich,

Ann Extern· Medii979;90:945-948]. However, it was found that not all warts are suitable for; intralesional bleomycine, the treatment .exhibit significant systemic drug 4 176876/3 exposure and significant local adverse and side effects. In addition, multiple treatments are required to achieve substantial success.

Summarizing various published reports indicates that topical standard salicylic acid treatment results, at best, in 40 % cure rate after 4 weeks compared to 8 % cure in the placebo group. Treatment with trichloro acetic acid typically results in 64-81 % cure rate, whereby treatment with 5-fluorouracil typically results in even lower cure rates ranging from 10 to 50 %. Carbon dioxide laser evaporation for recalcitrant warts results in 31-86 % cure rate. This treatment, however, may result in significant morbidity.

Using superpulsed mode to overcome these limitations was found to convey only a slight advantage. Comparable results were obtained with infrared coagulation. Early studies with pulsed dye lasers showed promising results, which have not been confirmed yet by later studies.

Since recalcitrant and recurrent warts are more common in patients with a cell- mediated immune deficiency state, it is suggested that spontaneous regression or successful treatment depend on either naturally or iatrogenically related stimulation of immunity [Robson et al. J Am Acad Dermatol, 2000;43(2 Pt 1):275-80]. Thus, several systemic and topical immunotherapies for warts have been reported, including squalic acid dibutylester, levamizole, and interferons beta and gamma. The efficacy of these therapies, however, was not definite.

The presently known methods for treating warts therefore suffer major disadvantages, in terms of both efficacy and adverse side effects associated therewith.

There is thus a widely recognized need for, and it would be highly advantageous to have novel methods of treating warts, devoid of the above limitations.

Various tellurium compounds have been described in the art as having immunomodulating properties. These compounds are taught, for example, in U.S. Patents Nos. 4,752,614; 4,761,490; 4,764,461 and 4,929,739, and in a recently filed WO 2006/030440 WO 2006/030438 and WO 2006/030437 (IL181913). U.S. Patent No. 4,752,614 teaches the use of certain tellurium compounds in the treatment of certain tumors, autoimmune diseases, immune diseases and infectious diseases. An anti- viral activity of these compounds 176876/2 was demonstrated in this patent in plants and animals, whereby the virus that is exemplified is West Nile Virus, which affects the central nervous system. The use of tellurium compounds to treat HPV and hence warts has never been suggested nor practiced hitherto.

SUMMARY OF THE INVENTION

The present invention provides a use of at least one tellurium-containing compound in the manufacture of a medicament for treating a skin or mucosal membrane ailment caused by a human papilloma virus (HPV), said skin or mucosal membrane ailment selected from verruca, verruca vulgaris, plantar warts, palmar warts, periungal warts, planar warts, mosaic warts, genital warts, venereal warts (condylomata acuminata), butcher’s warts, the at least one tellurium-containing compound selected from the group consisting of a compound having general Formula I:

O

<img img-format="tif" img-content="drawing" file="IL176876AD00021.tif" id="idf0001" />

Rio

I -c—Ri

I (R2-C-R3)t (R.-C-R^ (iq—C-R^v -c—Rs R, Y*

Formula I a compound having general Formula II: O-C—Ri

I

(R2-C-R3)t (R4-C-RJ io

<img img-format="tif" img-content="drawing" file="IL176876AD00022.tif" id="idf0002" />

Formula II 5a 176876/1 a compound having general Formula III: and

H

Rn-C—O,

Ris—C-0 \/ / \

H Ο C R]2

0 C R14 H

Formula III a compound having general Formula IV: O=C—O-C=O /Te\

R22-c-O O-C-R 15 m(R2iR2oC) (CRi6R17)n R19 c O.

o—C—R 18 \/

Te, / V —n

o=c-O O-C-O

Formula IV wherein: each of t, u and v is independently 0 or 1; each of m and n is independently an integer from 0 to 3; Y is selected from the group consisting of ammonium, phosphonium, potassium, sodium and lithium; X is a halogen atom; and each of R1-R22 is independently selected from the group consisting of hydrogen, hydroxyalkyl, hydroxy, thiohydroxy, alkyl, alkenyl, alkynyl, alkoxy, thioalkoxy, halogen, haloalkyl, carboxy, substituted carbonyl, alkylcarbonylalkyl, carboxyalkyl, acyl, amido, cyano, N-monoalkylamidoalkyl, Ν,Ν-dialkylamidoalkyl, cyanoalkyl, alkoxyalkyl, carbamyl, 5b 176876/1 cycloalkyl, heteroalicyclic, substituted sulfonyl, substituted sulfinyl, sulfate, amine, aryl, heteroaryl, phosphate, phosphonate and sulfoneamido.

The invention further provides a pharmaceutical composition identified for use in the treatment of a skin or mucosal membrane ailment caused by a human papilloma virus (HPV), comprising at least one tellurium-containing compound and a pharmaceutically acceptable carrier, said skin or mucosal membrane ailment selected from verruca, verruca vulgaris, plantar warts, palmar warts, periungal warts, planar warts, mosaic warts, genital warts, venereal warts (condylomata acuminata), butcher’s warts, the at least one tellurium-containing compound selected from the group consisting of a compound having general Formula I:

O

<img img-format="tif" img-content="drawing" file="IL176876AD00023.tif" id="idf0003" />

Rio l -C—R,

I (R2-C-R3)t (R4-C-R9u (Ro—C-R^v -c—Rs

Rp v-

Formula I a compound having general Formula II:

<img img-format="tif" img-content="drawing" file="IL176876AD00024.tif" id="idf0004" />

Formula Π 5c 176876/1 a compound having general Formula III:

Rn-C-C&gt; O—C—R 12 \/ R„—C / O“C—Rm

Η H

Formula ΠΙ and a compound having general Formula IV: o=c—θ—C—θ ^Te\ R22 c / O“C—r15 m(R2iR2oC) (CR16R17)n R19 C o—c—R: t/ O=c—/ o—C=o 18

Formula IV wherein: each of t, u and v is independently 0 or 1; each of m and n is independently an integer from 0 to 3; Y is selected from the group consisting of ammonium, phosphonium, potassium, sodium and lithium; X is a halogen atom; and each of R1-R22 is independently selected from the group consisting of hydrogen, hydroxyalkyl, hydroxy, thiohydroxy, alkyl, alkenyl, alkynyl, alkoxy, thioalkoxy, halogen, haloalkyl, carboxy, substituted carbonyl, alkylcarbonylalkyl, carboxyalkyl, acyl, amido, cyano, N-monoalkylamidoalkyl, Ν,Ν-dialkylamidoalkyl, cyanoalkyl, alkoxyalkyl, carbamyl, 5d 176876/1 cycloaikyl, heteroalicyclic, substituted sulfonyl, substituted sulfinyl, sulfate, amine, aryl, heteroaryl, phosphate, phosphonate and sulfoneamido.

DETAILED DESCRIPTION OF THE INVENTION

According to one aspect of the present invention there is provided a method of treating a skin or mucosal membrane ailment caused by a human papilloma virus (HPV) in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of at least one tellurium-containing compound.

According to further features in preferred embodiments of the invention described below, the tellurium-containing compound is selected from the group consisting of tellurium dioxide (TeO2), a complex of TeO2, a compound having general Formula I:

X X—Te

Rio

I

O

<img img-format="tif" img-content="drawing" file="IL176876AD00025.tif" id="idf0005" />

<img img-format="tif" img-content="drawing" file="IL176876AD00026.tif" id="idf0006" />

Formula I a compound having general Formula Π: WO 2005/069735 PCT/DL2005/000084 •10 C-Rj ί’

Te (R2-C-R3)t (jR^-C-R^ fo—C-R)v O c Rg

Rg

Formula II 5 a compound having general Formula HI:

Ru-C—Oc O—C—R12 R-13 ° o-c—R14 H 14 10.

Formula HI and a compound having general Formula IV: O=C—O-C=O Te; ‘ -V—O O-C—r15 m(R2iR2oC) (CR16R17)n R19-C-O. p—C—R] 18 15 \ /

/Te\ I

O=c-O O-C=O

Formula IV WO 2005/069735 PCT/IL2005/000084 ': · 7 . wherein.: each oft, u and. v is independently 0 or 1; each of m and n is independently an integer from 0 to 3; X is a halogen atom; 5 Y is selected from the group consisting of ammonium, phsophonium, potassium, sodium and lithium; and each of R1-R22 is independently selected from the group consisting of hydrogen, hydroxyalkyl, hydroxy, thiohydroxy, alkyl, alkenyl, alkynyl, alkoxy, thioalkoxy, halogen, haloalkyl, carboxy, carbonyl, alkylcarbonylalkyl, alkoxy, 10 . carboxyalkyl,· acyl,· amido, cyano, N-monoalkylamidoalkyl, N,N-dialkylamidoalkyl, cyanoalkyl, alkoxyalkyl, carbamyl, cycloalkyl, heteroalicyclic, sulfonyl, sulfinyl, sulfate, amine,/aryl, heteroaryl, phosphate, phosphonate and sulfoneamido.

Preferred tellurium-containing compounds are those having general Formula I above and those having general Formula II above. 15 More preferred compounds are those having one or more of the following features: t, u and v are each 0; each of Rj, Rg, R9 and Rio is hydrogen; X is a halogen atom, preferably chloro; and 20. Y is ammonium or phosphonium, preferably ammonium.

Additional- preferred compounds are those having general Formula ΠΙ above, wherein, preferably, each of R11-R14 is hydrogen.

Additional preferred compounds are those having general Formula IV above. More preferred compounds ih this category are those having one or more ofthe 25 . following features: ' j • hand m are' each 0; and eachof Ris, Ri8,Ri9 and R22 is hydrogen.

According·· ίθ further features in preferred embodiments of the invention described below, the administering is effected systemically. 30 According to. still further' features in the described preferred embodiments the therapeutically effective amount ranges, from about 0.01 mg/m2/day to about 10.0 •mg/m2/day. . WO 2005/069735 PCT/DL2005/000084 8

According, to· further features in preferred embodiments of the invention described below, the administering is effected topically.

According..to still further features in the described preferred embodiments topically administering the compound is effected by applying onto a treated skin or 5 mucosal membrane area a therapeutically effective amount of the at least one teUurium-eqhtaining compound described above.

According· to still further features in the described preferred embodiments the skin or mucosal membrane ailment is selected from the group consisting of verruca vulgaris, plantar warts, palmar warts, periungal warts, planar warts, mosaic warts, 10 genital warts, venereal warts (condylomata acuminata), butcher’s warts, malignant epidermodyspasia verruciformis, advanced intraepithelial dysplasia, cervical cancer, . mepidermodysplasia verruciformis, cutnaeous warts in immunosnppres'sed patients, laryngeal papillomas and oral papilloma.

According to still further features in the described preferred embodiments the 15 . method further, comprises administering to the subject an additional active agent.

The. additional active agent can be, for example, an antibiotic agent, an . antimicrobial agent; an anti-acne agent,· an antibacterial agent, an antifungal agent, an antiviral agent; a steroidal anti-inflammatory agent, anon-steroidal anti-inflammatory agent, an anesthetic;· agent, an antipruriginous agent, an antiprotozoal agenf an anti- 20 oxidant, a chemotherapeutic agent, an antidepressant, an anti histamine, a vitamin, a hormone, a keratolytic agent and an antidandruff agent.

According, to still further features in the described preferred embodiments the method further comprises administering to the subject an additional active agent that is capable of.treating the skin or mucosal membrane ailment caused by the HPV. 25 · According io'.still further features in the described preferred embodiments the tellurium-containing.compound forms a part of a pharmaceutical composition, which further comprises a pharmaceutically acceptable carrier.

Hence; ^according to another aspect of the present invention there is provided a • pharmaceutical'· cornposition identified for use in the treatment of a skin or mucosal 30 membrane ailment caused by a human papilloma virus (HPV), comprising at least one tellurium-containing compound as' described hereinabove and a pharmaceutically acceptable carrier. : WO 2005/069735 PCT/IL2005/000084 9

According to: further features in preferred embodiments of the invention described below, a concentration of the at least one tellurium-containing compound ranges from about Q.01 weight percent to about 50 weight percents of the total weight of the composition. 5 According to still further features in the described preferred embodiments the concentration of the at least one tellurium-containing compound ranges horn about 5 weight percents to. about 25 weight percents of the total weight of the composition.

According to. still further features in the described preferred embodiments, when used for topical application, the pharmaceutical composition is being in a form 10 selected horn the group consisting of a cream, an ointment, a paste, a gel, a lotion, a milk, a suspension, a solution, an aerosol, a spray, a foam, a shampoo, a mousse, a serum, a swab, a pledget, a pad, a tincture, a patch and a soap.

According, to still further-features in the described preferred embodiments the pharmaceutical composition further comprises at least one additional active agent, as 15. . described hereinabove.

According-to. still further features in the described preferred embodiments the pharmaceutical composition further comprises at least one ingredient such as, but not limited to, a humectant, a deodorant agent, an antiperspirant, a sun screening agent, a sunless tanning agent, a hair conditioning agent, a pH adjusting agent, a chelating 20 agent, a preservative, an emulsifier, an occlusive agent, an emollient, a thickener, a .solubilizing agent, apenetration enhancer, an anti-irritant, a colorant, a propellant and a surfactant.

According -to still further features in the described .preferred embodiments the pharmaceutical composition has a pH that ranges from 4 to 7. 25 According to still further features in the described preferred embodiments the pharmaceutical composition has a pH that ranges from 4 to 6. . . The present invention successfully addresses the shortcomings of the presently known configurations by providing novel compositions and methods utilizing same for treating warts and delated ailments caused by HPVs, which are highly efficient, and 30 . induce minimal or-.-no/adverse side effects.

Unless otherwise defined, all technical and scientific terms used herein have - the same meaning-as commonly understood by one of ordinary'skill in the art to which - this invention belongs. Although methods and materials similar or equivalent to those WO 2005/069735 PCT/IL2005/000084 10 ' described herein can be used in the practice or testing of the present invention, suitable methods and. .materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. 5 As used-herein, the term “treating” includes abrogating, substantially inhibiting, . slowing ,or reversing the progression of a condition, substantially ameliorating clinical or aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.

The term “comprising” means that other steps and ingredients that do not 10 affect the final result can he added. This term encompasses the terms "consisting of' and "consisting essentially of'.

The phrase "consisting essentially of' means that the composition or method may include additional-ingredients and/or steps, but only if the additional ingredients and/or steps do-not materially alter the basic· and novel characteristics of the claimed 15 composition or.method.

The term "method" refers to manners, means, techniques and procedures for accomplishing- a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the' chemical, 20 pharmacological, biological,-biochemical and medical arts.

The term “active ingredient” refers to a pharmaceutical agent including any natural or. synthetic chemical , substance that subsequent to its application has, at the •very least, at least one desired pharmaceutical or therapeutic effect.

The term "therapeutically effective amount" or “pharmaceutically effective •25 amount” denotes that dose of an active ingredient or a composition comprising the . active ingredient· that will provide the therapeutic effect for which the active • ingredient is indicated, herein, treating an HPV-caused ailment

As .used herein, the singular form "a," "an,", and "the" include plural references unless the context· clearly dictates otherwise.' For example, the term "a compound" or 30 ' "at least one compound" may include a plurality of compounds, including mixtures thereof.

Throughoiit-this disclosure, various aspects .of this invention can be presented ' in a range format It' should he understood that the description in range format is ' WO 2005/069735 PCT/IL2005/000084 11 merely for convenience and. brevity and should not he construed as an inflexible limitation on· the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range 5 such as from 1 to 6 should be considered to have specifically disclosed subranges such as fiom f ,to 3( from 1 to 4, from 1 to 5, fiom 2 to 4, fiom 2 to 6, from 3 to 6 etc., as well as individualnumbers within that range, for example, 1, 2, 3,4, 5, and 6. This applies regardless of the breadth of the range.

Whenever , a numerical range is indicated herein, it is meant to include any 10 cited numeral (fractional or integral) within the indicated range. The phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges front” a first indicate number “to” a second indicate number are used herein interchangeably and are meant' to include the first and second indicated numbers .and all the· fractional and integral numerals therebetween. 15

BRIEF DESCRIPTION OF THE DRAWINGS

The. invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed .that the particulars shown are by' way of example and for purposes of 20 illustrative discussion of the preferred embodiments of the present invention only, and •are presented'in the danse of providing what is believed to he the most· useful and readily understood .· description of - the principles . and conceptual aspects of the invention.· In .this, regard, no attempt is made to show structural details' of the .· invention· in more detail than is necessary for a fundamental understanding of the 25 invention, the description taken with the drawings making apparent to those skilled in . the art how the several forms of the invention may be embodied in practice.

In the drawings: FIG. 1· is aphoto'graph of the perianal area of a patient afflicted with condyloma warts, as described in Example'2, before treatment; 30 FIG. 2 is a photograph of the perianal area of a patient afflicted with condyloma warts, as describedin. Example 2, following about two weeks of treatment with an . exemplary composition according to the present invention; WO 2005/069735 PCT/IL2005/000084 12

FlG. 3 is a photograph of the perianal area of a patient afflicted with condyloma warts, as described in Example 2, following about four weeks of treatment with an exemplary composition according to the present invention; FIG. 4 is a photograph of the perianal area of a patient afflicted with condyloma 5 warts, as described in Example 2, following about six weeks of treatment with an ' exemplary composition according to the present invention; FIG. 5 is a photograph of the perianal area of a patient afflicted with condyloma warts, as described in Example 2, following about eight weeks of treatment with an exemplary composition according to the present invention; 10 Fig.'6 is a photograph of a patient afflicted with verrucca lesion on the hand, as described in'Example.3, before treatment; .FIG. 7 is' a photograph of a patient afflicted with verrucca lesion on the hand, as described in Example 3, following about four weeks of treatment with ah exemplary composition according to the present invention; 15 FIG. 8 is a .photograph of a patient afflicted with verrucca lesion on the hand, as described in Example 3, following about ten weeks of treatment with an exemplary composition, according to the present invention; FIG. 9 is a'.'photograph of a patient afflicted with verrucca lesions on the hand, as described in Example 4, before treatment; 20 FIG. 10 is- aphotograph of a patient afflicted with verrucca lesions on the hand, as described in Example 4, following about two weeks of treatment with an exemplary composition'according to the present invention; · • FIG. ll.is a'phbtograph of a patient afflicted'with verrucca lesions on the hand,· as described, in Example 4, following about four weeks of treatment with an exemplary 25 composition according to the present invention; FIGs. 12a-c are photographs of the .genital area of a patient afflicted with condyloma warts, as. described in Example 4, before treatment; FIGs. 13a-h\ are photographs of a patient afflicted with condyloma warts, as described in Example 5, following about two weeks of treatment with an exemplary 30 cream composition' according to the present-invention; FIGs. 14a-b' are photographs of .the genital area of a patient afflicted with condyloma warts, as described in Example 5, following about four weeks of treatment ' with an exemplary cream composition according, to the present invention; . WO 2005/069735 PCT/IL2005/000084 13 FIGs. I5a-b are photographs of the genital area of a patient afflicted with condyloma warts,· as described in Example 6, before treatment; FIGs. .I6a-c are photographs of the genital area of a patient afflicted with condyloma warts,· as described in Example 6, following about two weeks of treatment 5 with an exemplary, cream composition according to the present invention; FIG. · 17 is a..photograph of the genital area of a patient afflicted with condyloma warts, as described in Example 6, following about four weeks of treatment with an exemplary cream composition according to the present invention;; FIG. 18 is a photograph of the genital area of a patient afflicted with condyloma 10 warts, as described ih Example 7, before treatment; FIG. 19 is a photograph of the genital area of a patient afflicted with condyloma warts, as described in .Example 7, following· about two weeks of treatment with an exemplary cream composition according to the present invention; FIG. 20 is a photograph of a patient afflicted with condyloma warts in the anus, 15 ' as described in Example 8, before treatment; FIG, 21 is a photograph of a patient afflicted with condyloma warts in the anus, as described' in Example-8, following two days of treatment with an exemplary cream .composition according to the present invention; ’ • FIG).22'is a photograph of a'patient afflicted with condyloma warts in the anus, 20 ' as described in Example 8, following about 5 weeks of treatment with an exemplary cream composition according to the present invention; FIG. '23 is a photograph of a patient afflicted with condyloma warts in the anus, as described in Example 8, following about 8 weeks of treatment with an exemplary cream composition according to the present invention; 25 FIGs. ;24a-b are. photographs of a patient afflicted with verruca vulgaris in both hands, as. described iriExample 9, before treatment; FIGs. 25a-b are photographs of a patient afflicted with verruca vulgaris in both hands, as described in Example 9, following .about 3 weeks of treatment with an exemplary cream composition according to the present invention; · 30 . FIGs'.· 26a-b?are photographs of a patient afflicted with verruca yulgaris in both hands, as described -ia’ Example 9, following about 6. weeks of treatment with an exemplary cream, composition according to the present invention. WO 2005/069735 PCT/IL2005/000084 ί4 FIGs. 27a-d' are photographs of the genital area of a patient afflicted with-condyloma warts, as described in Example 10, before treatment (Figure 27a) and following about 4 weeks (Figure 27b), about 6 weeks (Figure 27c) and about 8 weeks (Figure 27d) treatment with an exemplary cream composition according to the present 5 invention; FIGs. 28a-d are photographs of the genital area of a patient afflicted with . condyloma.warts, as described in Example.il, before treatment (Figure 28a) and following about 2 weeks (Figure 28b), about 4 weeks (Figure 28c) and about 7 weeks (Figure 28d) treatment with an exemplary cream composition according to the present 10 · invention; FIGs. 29a-e are photographs of the anus of a patient afflicted with condyloma warts, as described in Example 12, before treatment (Figure 29a) and following about 2 weeks (Figure; 29bj,·· about 5 weeks (Figure 28c), about 8 weeks (Figure'29d) and • about 10 weeks (Figure 29e) treatment with an exemplary cream composition accdrding 15 . to the present invention; and FIGs. -30a-d are photographs of the anus of a patient afflicted with condyloma warts, as described ih Example 13, before treatment (Figure 30a) and following about 5 weeks (Figure 30b), about 7 weeks (Figure 30c) and about 9 weeks (Figure 30d) • treatment with an exemplary cream composition according to the present invention. 20

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present' invention is of novel compositions of tellurium-containing ' compounds which .'can be efficiently used for treating skin and mucosal membrane ailments caused by HPVs. The present invention is therefore further of methods of 25 treating such ailments, using tellurium-containing compounds. Specifically, the methods-and Compositions of the present invention can he used to treat any clinical • manifestation of HPVs, such as, for example, common warts (e.g., verruca vulgaris), •genital and venereal warts (e.g., condylomata acuminata), butcher’s warts, malignant epidermodyspasia verruciformis, cervical cancer, mepidermodysplasia verruciformis, 30 cutnaeous warts in immunosuppressed patients, laryngeal papillomas and oral papilloma. WO 2005/069735 PCT/IL2005/000084 15

The principles and operation of the compositions and methods according to the present' invention·· may be better understood with reference to the drawings and accompanying descriptions.

Before explaining at least one embodiment of the invention in detail, it is to be 5 understood that the invention is not limited in its application to the details set forth in the following description· or exemplified by-the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting. 10 As mentioned· in the Background section hereinabove, telluriumrcontaining compounds have been described in the art as immunomodulators. A particularly effective family of tellurium-containing compounds is described, for example, in U.S. . . Patents . Nos. 4,752,614; 4,761,490; 4,764,461 and 4,929,739. The immunomodulatmg; properties of this family of tellurium-containing compounds is 15 · described, for’example, in U.S. Patents Nos. 4,962,207, 5,093,135,. 5,'102,908 and 5,213,899, which are all incorporated by reference as if fully set forth herein.

One of the most promising compounds described in these patents is ammonium tnchloro(dioxyethylene-0,0’)tellurate, which is also referred to herein and in the art as AS101. Asis widely described in the art, AS 101, as a representative 20 example of the family of tellurium-containing compound discussed hereinabove, exhibits potent antiviral ["Antibabesial effect of the immunomodulator AS 101 in •mice: role of increased production of nitric oxide". Parasite Immunol 1996 Jun; "The ' antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung, adenocarcinoma". J Immunol 1996 Feb; "The protective role of the 25 ' . immunomodulator AS 101 against chemotherapy-induced alopecia studies on human and animal models". Int J Cancer 1996 Jan; and "Mechanism of radioprotection • conferred by the immunomodulator AS101". Exp Hematol 1993 Jan], tumoricidal , ["Effect of-.the immunomodulator AS 101 on chemotherapy-induced multilineage ’ myelosuppression, thrombocytopenia, and anemia in mice". Exp Hematol 1995 Dec; 30 and "Restoration of murine cytomegalovirus (MCMV) induced myelosuppression by • ΑΕΊ/Λ". Immunol Lett 1994 Dec] and adjuvant activity.

It has been suggested that AS101, as well as other1 tellurium-containing immunomodulators,. stimulate the innate and acquired arm of the immune response. It WO 2005/069735 . PCT/IL2005/000084 16 is a potent inducer of interferon (TFN) in mice ["Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with EL-10 inhibition and increase in TNF-alpha levels". J Immunol 1997-Sep-, "The immunomodulator -AS-101 inhibits EL-10 release and augments TNF alpha and.IL-1' 5 alpha release by-mouse and human mononuclear phagocytes". Cell Immunol 1997 Mar, "The antitumoral effect of the. immunomodulator AS 101 and paclitaxel (Taxol) in a murine, model of lung adenocarcinoma". J Immunol 1996 Feb] and humans ["Effect of the immunomodulator AS101 on chemotherapy-induced multilineage myelosuppression, thrombocytopenia, and anemia in mice". Exp Hematol 1995 Dec], 10 AS101, as .well as other tellurium-containing immunomodulators, have also· been shown to. induce the secretion of a spectrum of cytokines, such as IL-1, IL-6 and TNF-α. The· macrophages have been characterized as the main target for AS 101 ["Up-regulation by ammonium trichloro(dioxoethylene-0,0') tellurate (AS101) of Fas/Apo-1 expression on B16 melanoma cells:. implications for the antitumor effects 15 of AS101". JTmmunol 1998 Oct] and it found to inhibit EL-10 at the m-RNA level while increasing atithe same time the EL-12:

Other.'publications describing the immunomodulation properties of AS101 include, for example,· "The immunomodulator AS101 restores T(H1) type of response. suppressed by.. Babesia rodhaini .in BALB/c mice". Cell Immunol 1998 Feb', 20 ' "Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101". J Natl Cancer Inst 1996 Sep-, "AS-101: a modulator of in vitro T-cell proliferation". Anticancer Drugs 1993 Jun; "The immunomodulator AS 101 administered orally as a chemoprotective and radioprotective agent". Int J Immunopharmacol 1992 May; "Inhibition of the reverse transcriptase activity and 25 replication of human immunodeficiency virus type 1 by AS 101 in vitro". AIDS Res Hum Retroviruses 1992 May; "Immunomodulatory effects of AS101 on interleukin-2 . production and T-lymphocyte function of lymphocytes treated with psoralens and ultraviolet· A”.'.· Photodermatol Photoimmunol Photomed 1992 Feb; "Use and mechanism of, action of AS101 in protecting hone marrow colony forming units- 30 . granulocyte-macrophage following purging with ASTA-Z 7557". Cancer Res 1991

Oct 15; "The effect of the immunomodulator agent AS101 on interleukin-2 production in systemic lupus erythematosus (SLE) induced in mice by a pathogenic anti-DNA antibody". Clin Exp .Immunol 1990 Mar, "Toxicity study in fats of a WO 2005/069735 PCT/IL2005/000084 17 tellurium based immunomodulating drug, AS-10.1: a potential drug for AIDS and cancer patients". Arch Toxicol 1989; "The biological activity and immunotherapeutic properties of .AS-101, a synthetic organotellurium compound". Nat Immun Cell Growth Regul 1988; and "A new immunomodulating compound (AS-101) with 5 potential therapeutic application". Nature 1987 Nov, ; AS 1,01, as· well as other tellurium-containing immunomodulators, are therefore . capable of skewing the immune response, towards a Thl phenotype. This type of response .is crucial against intracellular pathogens such as viruses:

Furthermore, toxicity tests have showed that LD50 values in rats following 10 intravenous and intramuscular dosage of AS 10.1 are 500-1000 folds higher than the immunology effective dose. These tellurium-containing compounds are therefore further characterized as substantially non-toxic.

Based' on these findings, while conceiving the present invention, it was envisioned that since AS 101 is a potent modulator of the immune response from Th2 15 to Thl response, and. is further characterized as a substantially non-toxic agent, this tellurium-containing, compound, as well as other tellurium compounds of this family, could serve as .potent therapeutic agents against infections caused by HPV, devoid of the disadvantages : associated with .the presently known agents for treating HPV infections described hereinabove. 20 itshoiild be noted in this respect that although AS101 has been shownto exert an anti-viral activity, in· studies conducted heretofore, its efficacy as an anti-viral agent against human viruses was found to he insufficient.

As is- further mentioned hereinabove, another class of tellurium-containing compounds has been recently disclosed in U.S. Provisional Patent Application No. 25 60/610,660. As taught, in this patent application, this class of tellurium compounds was also shown to exert immunomodulating properties and therefore, it .was further envisioned that these compounds, could also serve as potent therapeutic agents against infections caused by. HPV. • As is demonstrated in the' Examples section that follows, while reducing the 30 present invention to . practice, it was indeed found that treating human patients afflicted with .various HPV infections with a tellurium-containing compound such as ’· AS 101· .was .highly efficient, resulting in high treatment responsiveness and minimized •sideeffects. . .·.·. · WO 2005/069735 PCT/IL2005/000084 18

Hence,, according to one aspect of the present invention there is provided a method of.treating a· skin or mucosal membrane ailment caused by HPV, which is effected by administering to a subject in need thereof a therapeutically effective amount of one or.moretellurium-containing compounds. 5 · As used herein, the phrase "tellurium-containing compound" encompasses any compound that includes one or more tellurium atoms and exhibits immunomodulating properties.

The' phrase· "immunomodulating properties" includes any effect of the compound on the. immune response of a subject. Exemplary immunomodulating 10 properties can be manifested, for example, by an effect on cytokines secretion, interleukins production, lymphocytes function, and the like.

The. compound can he, for example, an inorganic tellurium-containing compound such as, for example, tellurium· dioxide (TeC&gt;2), halogenated tellurium, sulfonated tellurium, phsophorylated tellurium, as well as salts thereof (e.g., 15 ammonium.salt's, alkaline salts, phosphonium salts and the like) and any complexes thereof.

The compound can alternatively be an organic tellurium-containing compound which includes, one or more tellurium atoms and one or more organic moieties that are attached thereto.'. . 20 . Representative' ·examples of inorganic tellurium-containing compounds .that were shown'to exert immunomodulating properties and hence are particularly· useful in the context of the present invention include, forexample, TeC&gt;2 and TeX, wherein X is halogen. .

As used herein, the term "halogen", which is also referred to herein 25 interchangeably as "a halogen atom" or "halo", includes chloro (Cl), bromo (Br), iodo (I) and fluoro (F).. .

Also included are compounds that form TeC&gt;2 in aqueous solutions, preferably in the form of a complex such as, for example, a TeC&gt;2 complex with citric acid or . ethylene glycol. A representative example of the latter is the complex 30 TeOfHOCHiCHaQHN^Cl.

Organic teRurium-containing compounds that were shown to exert ' immunomodulating-pfoperties and hence are particularly useful in the context of the present' invention'include, for example, ammonium salts, or any other salts, of WO 2005/069735 PCT/IL2005/000084 19 halogenated tellurium-containing compounds having a bidentate cyclic moiety . attached to the tellurium atom. The bidentate cyclic moiety is preferably a di-oxo moiety having two oxygen, atoms attached .to the tellurium atom. Alternatively, the bidentate cyclic moiety can be a di-thi'o moiety, in which two sulfur atoms are 5 attached to the tellurium atom.

Preferred, compounds in this category' are collectively represented by the general Formula I: 10

<img img-format="tif" img-content="drawing" file="IL176876AD00027.tif" id="idf0007" />

Formula I Y"

In the.general Formula I above, each of t, u and v is independently 0 or 1, such that· the compound may include a five-membered ring, a six-membered ring, a seven- . membered ring of .'an eight-membered ring. Preferably, each of t, u and v is 0, such •15- . that the compound, includes a five-membered ring. X is a halogen atom, as described hereinabove, and is preferably chloro. Ύ is selected fiom the group consisting of ammonium, phsophonium, ' potassium, sodium and hthium, and is preferably ammonium. pach of Ri-Riq is independently selected from the group consisting of 20 hydrogen,, hydroxyalkyl, hydroxy, thiohydroxy, alkyl, alkenyl, alkynyl, alkoxy, thioalkoxy, halogen, haloalkyl, carboxy, carbonyl, alkylcarbonylalkyl, alkoxy, carboxyalkyl, acyl, amido, cyano, N-monoalkylamidoalkyl, N,N-dialkylamidoalkyl, cyanoalkyl, alkoxyalkyl,. carbamyl, cycloalkyl, heteroalicyclic, sulfonyl, sulfinyl, / sulfate, amine, aryl,· heteroaryl, phosphate, phosphonate and sulfoneamido. '25 . As used herein, the term."alkyl" refers- to a saturated aliphatic hydrocarbon including straight chain and branched chain groups. Preferably, the alkyl group has 1 WO 2005/069735 PCT/IL2005/000084 20 to 20 carbon atoms. Whenever a numerical range; e.g., "1-20", is stated herein, it - implies that the group, in this case the alkyl group, may contain 1 carbon atom, 2 carbon atoms, '3 carbon atoms, etc., up to and including 20 carbon atoms. More preferably, the ajkyl is a· medium size alkyl having 1 to 10 carbon atoms. Most 5 preferably,· unless .otherwise indicated, the alkyl is a lower alkyl having 1 to 5 carbon • atoms. The alkyl group may be substituted or unsubstituted. When substituted, the substituent group can be, for example, hydroxyalkyl, tribaloalkyl, cycloaikyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfate, cyano, nitro, sulfonamide, 10 phosphonyl, phosphinyl, carbonyl, thiocarbonyl, carboxy, thiocarboxy, carbamate, thiocatbamate, .amido, sulfonamido, and amino, as these terms are defined herein.

As used herein, the term "hydroxyalkyl" refers to an alkyl, as this term is defined ’ . herein, substituted by a hydroxy group, as defined herein, and includes, for example, hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxy-n-butyl. 15 The terrn’haloaikyr refers to an alkyl, as this term is defined herein, substituted by a halogen, as defined herein, and includes, for example, chloromethyl, 2-iodoethyl, 4-bromo-n-butyl, iodoethyl, 4-bromo-n-pentyl and the like.

The term .'"alkanoyloxy" refers to a carbonyl group, as define herein'and includes, for example, acetyl, propionyl, butanoyl and ihe like. 20 The term "carboxyalkyl" refers to an alkyl, as this term is defined herein, substituted by. a carboxy group, as defined herein, and includes, for example, carboxymethyl, carboxyethyl, ethylenecarboxy and the like.

The tettn..’’alkylcarbonylalkyl" refers to an alkyl, as this term is defined herein, substituted by'a.·· carbonyl group, as defined herein, and includes,. for example, 25 - methanoylmethyl, ethanoylethyl and the like'.

The term "amidoalkyl" refers to an alkyl, as this term is defined herein, substituted by-an amide group, as defined herein, and includes, for example, - CH2CONH2; -CH2CH2CONH2; -CH2CH2CH2CONH2 and the like.

The term ."cyanoalkyl" refers to an alkyl, as this term is defined herein, 30 substituted by:an.cyano group, as defined herein, and includes, for example, -CH2CN; - CH2CH2GN; CH2CHiCH2CN and Ihe like. WO 2005/069735- PCT/IL2005/000084 21

The term "N-monoalkylamidoalkyl" refers to an alkyl, as this term is defined herein, substitutedby.an amide group, as defined herein, in which one of R' and R" is an alkyl, and includes, for example, -CH2CH2CONHCH3, and -CH-2CONHCH2CH3.

The term Ν,Ν-dialkylamidoalkyl refers to an alkyl, as this term is defined herein, . 5 substituted by an amide group, as defined herein, in which both R' and R" are alkyl, and ' includes, for example,;.-CH2CON(CH3)2; CH2CH2CON(CH2-CH3)2 and the like. A "cycloaikyl" group refers to an all-carbon monocyclic or fused ring (i.e., rings which share an.adjacent pair of carbon atoms) group wherein one of more of the rings does not have a completely .conjugated pi-electron system. Examples, without 10 limitation, of. cycloaikyl groups are cyclopropane, cyclobutane, cyclopentane, cyclopentene,.'.cyclohexane, cyclohexadiene, cycloheptane, cycloheptatriene, and adamantane. · A cycloaikyl group may be substituted or unsubstitut'ed. When substituted, the substituent group can he, for example, alkyl, hydroxyalkyl,. trihaloalkyl, cycloaikyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, halo, 15 hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, cyano, nitro, phosphonyl, phosphinyl, carbonyl, thiocarbonyl, carboxy, thiocarboxy, carbamate, thiocarbamate, amido, sulfonamido, and amino, as these terms are defined .herein.

An "alkenyl" .group refers to an alkyl group which consists of at least two 20 carbon atoms and at least one carbon-carbon double bond.

An "alkynyl" .group refers to an alkyl group which consists of at least two carbon atoms and at least one carbon-carbon triple bond.

An "aryl"-group refers to an all-carbon monocyclic or fused-ring polycyclic (i.e., rings which’share adjacent pairs of carbon atoms) groups having a completely 25 conjugated .pi-electron system. Examples, without limitation, of aryl groups are phenyl, naphthalenyl and anthracenyl. The aryl group· may be substituted or . unsubstituted,·· When· substituted, the substituent group Gan he, for example, alkyl, .hydroxyalkyl, trihaloalkyl, cycloaikyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, .thiohydroxy, thioalkoxy, thioaryloxy, .-30 sulfinyl, sulfonyl, sulfate, cyano, nitro, phosphonyl, phosphinyl, phosphonium, ·. carbonyl, thipcarbonylj carboxy, thiocarboxy, carbamate, thiocarbamate, amido, • sulfonamido, .and amino, as these terms are defined herein. WO 2005/069735 PCT/IL2005/000084 22 A -"heteroaryl." group refers to a monocyclic or fused ring (z.e., rings which share an adjacent pair of atoms) group having in the ring(s) one or more atoms, such as, for example, nitrogen, oxygen and sulfur and, in addition, having a completely conjugated pi-electron system. Examples, without limitation, of heteroaryl groups 5 include pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrimidine, quinoline, isoquinoline and purine. Ihe heteroaryl group may be substituted or'unsubstituted. When substituted, the substituent group can be, for example, alkyl, hydroxyalkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, 10 thioaryloxy, sulfinyl, sulfonyl, sulfate, cyano, nitro, phosphonyl, phosphinyl, phosphonium,' carbonyl, thiocarbonyl, carboxy, thiocarboxy, carbamate, thiocarbamate, anudo, sulfonamido, and amino, as these terms are defined herein. A "heteroalicyclic" group refers to a monocyclic or fused ring group having in fhe rihg(s) one Ormore atoms such as nitrogen, oxygen and sulfur. The rings may also 15 have one- or ihore'double bonds. However, fhe rings do not have a completely conjugated pi-elecfron system. The heteroalicyclic may be substituted or unsubstituted. When, substituted, the substituted group can be, for example, lone pair electrons, alkyl, hydroxyalkyl, trihaloalkyl, cycloaliyl, alkenyl, alkynyl, aryl, heteroaryl,· heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, · 20 thioaryloxy,- sulfinylj sulfonyl, sulfate, cyano, nitro, phosphonyl, phosphinyl, phosphonium,. carbonyl, thiocarbonyl, carboxy, thiocarboxy, carbamate, thiocarbamate, amido, sulfonamido, and amino, as these terms are defined herein. Representative - examples are piperidine,· piperazine, tetrahydro furane, tetrahydropyrane, morpholino and the like. • - -25 -A "hydroxy'* group refers to an -OH group. ·

An "alkoxy" .group refers to both an -O-alkyl and an -O-cycloalkyl group, as- defined herein.-

An "aryloxy" group refers to both an -O-aryl and an -O-heteroaryl group, as defined herein.· 30 A "thiohydroxy" group refers to a -SH group. A "thioalkoxy" group refers to both an -S-alkyl group, and an -S-cyoloalkyl group, as defined herein. WO 2005/069735 PCT/IL2005/000084 23 . A "thioaryloxy" group refers to both an ,-S-aryl and an -S-heteroaryl group, as defined herein.' A "carbonyl" group refers to a -C(=O)-R’ group, where R' is hydrogen, alkyl, alkenyl, cycloalkyi, aryl, heteroaryl (bonded through a ring carbon) or heteroalicyclic 5 (bonded through a ring carbon) as defined herein. A "thiocarbonyl" group refers to a -C(=S)-R' group, where R' is as defined herein for R’. A "carboxy" group refers to a -C(=O)-O-R' or a -O-C(=O)-R’ group, where R' is as defined herein. 10 A "sulfinyl" group refers to an -S(=O)-R' group, where R' is as defined herein. A "sulfonyl" group refers to an -S(=O)2-R' group, where R' is as defined herein. A "sulfate"' group refers to a -O-S(=O)2-OR' group, where R' is as defined herein.' 15 A “sulfonamido” group refers to a -S(=O)2-NR’R’ ’ group or a R’ S(=O)2-NR’ ’, • with R’ is as defined herein· and R’ ’ is as. defined for R'. A "carbamyl" or "carbamate" group refers to an -OC(=O)-NR’R” group or a R”OC(=O)-NR’- group, where R’ and R” are as defined herein. A ."thiocarbamyl" or "thiocarbamate" group refers to an -OC(=S)-NR’R” 20 group or an R”OC(=S)NR’- group, where R’ and R” are as defined herein.

An "amino" group refers to an —NR’R” group where R’ and R” are as defined herein. .

An "amido" group refers to a -C(=O)-NR’R” group or a R’C(=O)-NR” group, where R’ and R?5 are as defined herein. 25 A !,nitro" group refers to an -NO2 group.' A "cyano" group refers to a -CsN group.

The teim ‘iphosphonyl” describes a -O-P(=O)(OR’)(OR") group, with R’ and R" as defined hereinabove.

The term “phosphinyl” describes a-PR’R" group, with R’ and R" as defined 30 . .hereinabove. '

As cited hereinabove, the compounds in this category' are salts of organic tellurium-containing compounds. The salts can be, for example, ammonium salts, WO 2005/069735 PCT/DL2005/000084 24 phsophonium salts and alkaline salts such as potassium salts, sodium salts, lithium salts and .the like.

Hence,Ύ in.Formula I above can he a phosphonium group, as defined herein, an ammonium group, as defined herein, potassium (K*), sodium (Na*) or lithium '5 (Li*).

As used herein, the term, "phosphonium".describes a -P*RR"R"' group, with •R’ and R" as defined herein and R"’ is as defined for R'. The term "phsophonium", as used herein, further refers to a -P*Ri group, wherein each of the six R substituents is independently as defined herein for R, R" and R'". 10 The term "ammonium" describes a -N+R'R"R'" group, with R', R" and R'" as defined herein)·

More preferred compounds in this category include compounds having the general. Formula I described above,· in which Y is ammonium or phosphonium, t, u andv are. each Ό, each of R1-R9 is hydrogen and Rio is hydrogen or alkyl. These 15 compounds can he represented by the following structure: X.

H -C—R Y* -CH, wherein R is hydrogen or alkyl, preferably methyl, and X is halogen, 20 preferably chloro.

The presently most preferred compound for use in the context of the present invention has the following structure: O-CH, \ /

Cl-Te cX X)—ch2 NH4* 25 WO 2005/069735 PCT/IL2005/000084 25-

This compound' is ammonium trichloro(dioxyethylene-0,0’)tellurate, which is also referred to herein and in the art as AS 101.

An additional exemplary compound in this category is: , O-CH,'

V

Cl-Te cf/ o—ch2

CL P+(CsH5)6

Additional representative examples of organic tellurium-containing compound that are suitable for. Use in the context of the present invention include halogenated tellurium having a bidentate cyclic moiety attached to the tellurium atom. The 10 bidentate cyclic moiety is preferably a di-oxo ligand having two oxygen atoms attached to toe tellurium atom. Alternatively, the bidentate cyclic moiety can be a dithio ligand, in which-two sulfur atoms are attached to toe tellurium atom.

Preferred compounds in · this category, can he represented by the general Formula Π: · . 15 χ. ^10 -C—Rj , 1 1 (R2—C-R3)t Te (Rt—C—R)u ο O' C Rg

Rj

. Formula II wherein t,-'u, y, X and Ri-Rio are as defined hereinabove. 20 More .preferred compounds are those in which t, u, and v are each 0, and X is chloro, such; as; but not limited to, the compound having toe following structure: WO 2005/069735 PCT/IL2005/000084 26

Cl-Te

Ck -CH, -CH,

The organic tellurium-containing compounds haying Formulae I and Π can be. readily prepared- by reacting tetrahalotelluride such as TeCfi with a dihydroxy •5 compound, as.-is described in detail in U.S. Patents Nos. 4,752,614, 4,761,490, 4,764,461 and-4,929,739.

Additional representative examples of organic tellurium-containing compound that are suitable for use in the context of the present invention include compounds in which two hidentate.cyclic moieties are attached to the tellurium atom. Preferably, 10 each of the cyclic-mpieties is a di-oxo moiety. Alternatively, one or more of the . cyclic moieties is a di-thio moiety.

Preferred compounds in this category are collectively represented by the general Formula HT. '·'

Η H

Rri C—O—C—Rn •15

Rj3 C θ o-c-R14 H 1

Formula HI wherein each of Rn-Rw is independently selected fiom the group consisting of '20· hydrogen,, hydroxyalkyl, hydroxy, thiohydroxy, alkyl, alkenyl, alkynyl, alkoxy, thioalkoxy,· halogen? haloalkyl, carboxy, .carbonyl, alkylcarbonylalkyl, alkoxy, carboxyalkyl,. acyl, ainido, cyano, N-monoalkylamidoalkyl, N,N-dialkylamidoa3kyl, cyanoalkyl, alkoxyalkyl, carbamyl, cycloalkyl, heteroalicyclic, sulfonyl, sulfinyl, • sulfate, amide; aryl, -heteroaryl,' phosphate, phosphonate and sulfoneamido, as these 25 terms are.defined herein.

More preferred compounds in this category are those in which each of Rn-Ri4 is hydrogen.· . WO 2005/069735 PCT/IL2005/000084 27

Additional· representative examples of organic tellurium-containing' compounds that are suitable for use in the context of the present invention include the recently disclosed bis-tellurium compounds having general Formula IV: O=c C—°

/T\ I R22—C-O · O-C-Rl •15 m(R-2lR2oC) (CR16R17)n r19—c—o. o—c—R, 18

X

/ \ —n O=c—o o-c O

Formula IV wherein'each of Ris-R^ is independently selected from the group consisting of hydrogen,, hydroxyalkyl, hydroxy, thiohydroxy, alkyl, alkenyl, alkynyl, alkoxy, 10 ' thioalkoxy, halogen; haloalkyl, carboxy, carbonyl, alkylcarbonylalkyl, alkoxy, carboxyalkyl,. acyl,··· amido, cyano, N-monoalkylamidoalkyl, N,N-dialkylamidoalkyl, cyanoalkyl, alkoxyalkyl, carbamyl, cydoalkyl, heteroalicyclic, sulfonyl, sulfinyl, sulfate,· amine,-.aryl,··.hetero aryl, phosphate, phosphonate and sulfoneamido, as these •terms are definedherein: and 15 ' · in and-h are each an integer from Oto 3.

Preferred compounds in this category are those in which m and n are each 0. The presently most preferred compound in this family is a compound in which R15, Ris, Rig and R22 are all hydrogen, and which has the following structure: WO 2005/069735 PCT/EL2005/000084 28 o=c— o—c—o . /Te\

HC-O O-CH

CH—O—CH

/ \ _n o=c—o o-c—O

Compoundshaving the general Fonnula IV can be readily prepared byreacting . substantially equimolar amounts of a tellurium tetralkoxide and a polycarboxylic acid. 5 These materials are combined in the presence of a water free organic solvent such as dried ethanol, dimethyl sulfoxide, i-propanol and the like. Generally the reaction may take place at ambient conditions but if desired higher or lower temperatures and higher or'lower pressures may be utilized.

Exemplary tellurium tetraalkoxide compounds that are usable in the preparation 10 of the compounds having general Formula IV above include, without limitation, tetramethoxide; tetfaethoxide, tetrapropoxide, tetraisopropoxide, tetrabutoxide, and tetrapentoxide tellerium compounds.

Useful· polycarboxylic acids include also polyhydroxy polycarboxylic and • hydroxy polycarboxylic acids. Exemplary polycarboxylic acids that are usable in the 15 preparation· of the .compounds having general. Formula IV above include, without limitation, tartaric acid; glutaric acid, succinicacid,'malonic acid, gluconic acid and the like.

Additional organic tellurium-containing compounds that are suitable for use in •the context of the present invention include those having the general Formula V: 20

Ra

Rd- e-Rb

Rc

Formula V WO 2005/069735 PCT/IL2005/000084 29 wherein each of Ra, Rb, Rc and Rd is independently selected from, the group consisting of halogen alkyl, aryl, cycloalkyl, alkoxy, aryloxy, thioalkoxy, thioaryloxy, carboxy, carbonyl, thiocarboxy, thiocarbonyl, carbamyl, and thiocarbamyl, as these terms are defined hereinabove, whereby at least one of Ra-Rd is not halogen, namely, is 5 selected from the group consisting of alkyl, aryl, cycloalkyl, alkoxy, aryloxy, thioalkoxy, thioaryloxy, carboxy, carbonyl, thiocarboxy, thiocarbonyl, carbamyl, and thiocarbamyl.

Compounds.inthis category include those in which one of Ra, Rb, Rc and Rd is halogen alkyl,. aryl, cycloalkyl, alkoxy, aryloxy, thioalkoxy, thioaryloxy, carboxy, 10' carbonyl, thiocarboxyj thiocarbonyl, carbamyl, or thiocarbamyl, whereby the others halogen'atoms, e.g., chloro.

Other compounds in this category include those in which two or three of Ra, Rb, Rc and Rd are' as described above and the others are halogens e.g., chloro.

Other compounds in this category include those in which each of Ra, Rb, Rc and 15 . Rd is as described hereinabove.

An exemplary compound in this category is PhTeCl3.

The compounds described above can be administered or otherwise utilized in this and other aspects of the present invention, either as is or as a pharmaceutically acceptable salt thereof.. '20 The phrase'· "pharmaceutically acceptable salt" refers to a charged species of the parent· compound· and its counter ion, which is typically used to modify the •solubility characteristics of the parent compound and/or to reduce any significant irritation to art- organism by the parent compound, while·not abrogating the biological' activity and properties of the administered compound. 25 As. is .demonstrated in the Examples section that follows, AS101, a representative· example of a tellurium-containing compound according to the present invention, was found to be highly efficient in treating various ailments caused by various HPVs, including verruca vulgaris and genital and anus condylomata acuminata. The treatment was accompanied with minimal or no adverse side effects 30 and the ailments· (e.g;, warts) were substantially completely removed.

The high efficiency of the treatment according to the present invention,· as compared with the .presently known methods of treating HPV-caused ailments, is attributed to ·· the immunomodulating and anti-viral activity of the tellurium- WO-2005/069735 PCT/BL2005/000084 30 containing compounds described above. As such, treatment with, the tellurium-containing compounds described above, affects not only the manifested visible lesions hut rather suppress the cause of the ailment — the virus itself. As a result, viral particles that may be lurking in normal-appearing areas surrounding the warts, 5 are also destroyed. This effect of the tellurium-containing compounds described herein is clearly demonstrated in, for example,.Figures 13a and 13b, where it can be seen that the area affected by the treatment (seen as black spots) is larger that the visible lesion area before treatment (see, Figures 12a-c).

The. method according to this aspect of the present invention can therefore be 10 efficiently utilized, for treating skin and mucosal membrane ailments caused by a HPV.

As rised herein, the phrase "a skin or mucosal membrane ailment caused by a HPV", which also referred to herein interchangeable as "HPV-caused ailment'!, encompasses' any ailment that is associated, either directly or’indirectly, with any

15 type of HPV

As is discussed hereinabove, to date, there are more than seventy identified distinct types' of HPVs. These different types have been subdivided into two large categories: cutaneous and mucosal. Since, as is further discussed hereinabove, some HPV-caused. ailments may develop into cervical cancer, these different virus types 20 have been further categorized in- this respect by their risk grade and therefore include low-risk'HPV types, moderate-risk HPV types and high-risk HPV types.

According to! an embodiment this aspect of the present invention, the method described above is .therefore further directed at treating moderate-risk and high-risk FP V types and thus'.at treating and preferably preventing the development of cancer. 25 Exemplaiy'skin and mucosal membrane ailments that are treatable by the method of this , aspect of the present invention therefore: include verruca vulgaris, plantar warts, palmar warts, periungal warts, planar warts, mosaic warts, genital warts, venereal warts (condylomata acuminata), butcher’s warts, malignant epidermodyspasia verruciformis, advanced intraepithelial dysplasia, cervical cancer, mepidermodysplasia - 30. verruciformis, cutnaeous warts in immnnosuppressed patients, laryngeal papillomas · and oral papilloma. .

The various ailments caused by HPVs are typically manifested in various skin areas and mucosal membranes, including, for example, hands, face, forearms,, elbows, WO 2005/069735 PCT/IL2005/000084 31 legs, nails and. anus, and genital areas such as the perianal area, perineum, vulva, penis, vagina, .-and.'in rare severe cases the cervix. Although rare, HPV-caused aliments can he also manifested on the oral mucosa, conjunctivae and larynx.

The compounds described above can he administered' to a subject afflicted by 5 an HPV-caused ailment by any of various systemic routes.

Suitable routes of systemic administration may, for example, include the' inhalation, oral, -buccal, rectal, transmucosal, transdermal, intradermal, transnasal, intestinal and/or parenteral routes; the intramuscular, subcutaneous and/or intramedullary, injection routes; the intrathecal, direct intraventricular, intravenous, 10 intraperitoneal·, ihtranasal, and/or intraocular· injection routes; and/or the route of direct injection into a tissue region of a subject of the present invention.

Whenadirunistering systemicaliy, a therapeutically effective amount of the tellurium-containing· compounds described herein may range, for example, from about 0.01 mg/m2/day to- about 10.0 mg/m2/day and thus can-.be for example, 0.01 15 mg/m2/day, 0.02 ing/m2/day, 0.03 mg/m2/day, 0.04 mg/m2/day, 0.05 mg/m2/day, 0.06· mg/m2/day, .0:07 mg/m2/day, 0.08 mg/m2/day, 0.09 mg/m2/day and 0.1 mg/m2/day. Preferably, when administered parenterally, the therapeutically effective amount is 0.1 mg/m2/day and higher and thus can be, for example, 0.2 mg/m2/day, 0.3 mg/m2/day, 0.4 mg/m2/day, 0.5'mg/m2/day, 0.6 mg/m2/day, 0.7 mg/m2/day, 0.8 mg/m2/day, 0.9 20 mg/m2/day, 1.0 mg/m2/day, 2.0 mg/m2/day, 3.0 mg/m2/day, 4.0 mg/m2/day, 5.0 mg/m2/day, and up to 10.0. mg/m2/day. When administered orally, a daily dose typically ranges between 10. mg and 150 mg.

As used herein,· the term "about" refers to ± 10 %.

Optionally and preferably, the compounds described above can be 25 administered to a ;.subject afflicted -by an HPV ailment by local routes, and more preferably, the compounds are administered, topically.

Topical , application of the tellurium-containing compounds described herein is preferably.· effected'by applying onto a treated skin or mucosal membrane area a therapeutically'effective amount the compound. · 30 The treated area-can he, for example, hands, face, forearms, elbows, legs, nails, anus, and genital areas such as the perianal area, perineum, vulva, penis, vagina, and if needed, the cervix.· " · · . WO 2005/069735 PCT/DL2005/000084 32 '

Herein, the phrase "treated area" encompasses the affected area (e.g., the wart(s)). as Well as the tissues surrounding the indicated area. The topical application is effected on and around the clinical manifestation (e.g., the wart(s)).

The method according to this aspect of the present invention can further 5 comprise, in addition to administering the tellurium-containing compounds described above, co-administration of an additional active agent The co-administration can be effected prior to; concomitant with or subsequent to the administration of the tellurium-containing compound. The additional active agent is used for providing an additive beneficial effect in terms of the ailment being treated, conditions associated 10 with the ailment being treated or other parameters such as psychological effects and prophylactic'effects. • Hence/. exemplary additional active agents according to this embodiment of present invention .-.include, without limitation, one or more, or any combination of an ' antibiotic· ageht,· an antimicrobial agent, an anti-acne agent, an antibacterial agent, an 15 antifungal agent, 'an antiviral agent, a steroidal anti-inflammatory agent, a nonsteroidal anti-inflammatory agent, an anesthetic agent, an antipruriginous agent, an antiprotozoalagent, an anti-oxidant, a chemotherapeutic agent, an antidepressant, an anti histamine, a vitamin, a hormone and an anti-dandruff agent.

Suitable anti-acne agents for use in this context of the present invention 20 include, without limitation, keratolytics such as salicylic acid, sulfur, glycolic, pyruvic acid, resorcinol, and.N-acetylcysteine and retinoids such as retinoic acid and its derivatives (e.g., cis and trans, esters).

Suitable antibiotics for use in this context of the present invention include, without limitation,'benzoyl peroxide, octopirox, erythromycin, zinc,. tetracyclin, 25 triclosan,· azelaic acid and its derivatives, phenoxy ethanol and phenoxy proponol, ethylacetate, clindamycin and meclocycline; sebostats such as flavinoids; alpha and beta hydroxy.;'acids;'.'and..bile salts, such as scymnol sulfate' and its derivatives,, deoxycholate and. cholate.

Representative examples of non-steroidal anti-inflammatory agents that are • 30 ' . usable in this, -.context of the present invention include, without limitation, oxicams, such as piroxicam, Noxicam, tenoxicam, .sudoxicam, and CP-14,304; salicylates, such as aspirin; disalcid,·; benorylate, trilisate, safapryn, solprin, diflunisal, and fendosal; acetic acid derivatives, such as diclofenac, fenclofenac, indomethacin, sulindac, WO 2005/069735 PCT/IL2005/000084 tolmetin,. isoxepac,: furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepirac,..clindahac, oxepinac, felbinac, and ketorolac; fenamates, such as mefenamic,-meclofenamic, flufenamic, niflumic, and tolfenamic acids; propionic acid derivatives, such as. ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, 5 fenoprofen, fenbufen, indopropfen, pirprofen, caiprofen, oxaprozin, pranoprofen, .iniroprofen, 'tioxaprofen, suprofen, alminoprofen, and tiaprofenic; pyrazoles, such as phenylbutazone, oxypheributazone, feprazone, azapropazone, and trimethazone. Mixtures of these non-steroidal anti-inflammatory agents may also be employed, as well as the dermatologically acceptable salts and esters of these agents. For example, 10 etofenamate,· a flufenamic acid derivative, is particularly useful for topical application.

Representative examples of steroidal anti-inflammatory drugs include, without limitation,· corticosteroids such as hydrocortisone, hydroxyltriamcinolone, alpha-methyl dexamethasone, dexamethasone-phosphate, beclomethasone dipropionates, 15 clobetasol .vaiorate, · .desonide, · desoxymethasone, desoxycortieosterone acetate, dexamethasphe, .dichlorisone, diflorasone diacetate, diflucortolone valerate, . fluadrenolone, fluclorolone acetonide, fludrocortisone, flumethasone pivalate, . fluosinolorie ' acetonide, fluocinonide, flucortine butylesters, fluocorfolone, .fluprednidene (fluprednylidene) acetate, flurandrenolone, halcinonide, hydrocortisone •20 acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetonide, cortisone,.' cortodoxone, flucetonide, fludrocortisone,·, difluorosone diacetate, fluradrenolone, fludrocortisone, diflurosone diacetate, fluradrenolone acetonide, medrysone, amcinafel,. amcinafide, betamethasone and the balance of its esters, chloroprednisone, chlorprednisone acetate, clocortelone, clescinolone, dichlorisone, 25 ’. difluiprednate, ’· fhicloronide,- flunisolide, fluoromethalone, fluperolone, fluprednisolone,..hydrocortisone valerate, .hydrocortisone cyclopentylpropionate, hydrocortamate, · ·.. meprednisone, paramethasone, prednisolone, prednisone, beclomethasorie dipropionate, triamcinolone, and mixtures thereof.

Suitable antipruritic agents include, without limitation, pharmaceutically 30 acceptable salts of methdilazine and trimeprazme.

Non-limiting examples of anesthetic drugs that are suitable for use in context .of the present invention include pharmaceutically acceptable salts of lidocaine, WO 2005/069735 PCT/IL2005/000084 34 bupivacaine, cblorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxine and phenol. •Suitable antimicrobial agents, includingantibacterial, antifungal, antiprotozoal and antiviral agents, for . use in context of the present invention include, without 5 limitation, beta-lactam drugs, quinolone drugs, ciprofloxacin, norfloxacin, tetracycline,, erythromycin, amikacin, triclosan, doxycycline, capreomycin, chlorhexidine'; ' chlortetracycline, oxytetracycline, clindamycin, ethambutol, metronidazole, pentamidine, gentamicin, kanamycin, lineomycin, methacycline, methenamine, minocycline, neomycin, netilmicin, streptomycin, tobramycin, and 10 miconazole. Also included are tetracycline hydrochloride, famesol, erythromycin estolate, erythromycin stearate (salt), amikacin sulfate, doxycycline hydrochloride, chlorhexidine · gluconate, . chlorhexidine hydrochloride, chlortetracycline .· hydrochloride, oxytetracycline hydrochloride, clindamycin hydrochloride, ethambutol hydrochloride,-"metronidazole hydrochloride, pentamidine hydrochloride, gentamicin 15 sulfate, kanamycin . sulfate, lineomycin hydrochloride, methacycline hydrochloride, methenamine X hippurate, methenamine mandelate, minocycline hydrochloride, • neomycin sulfate; 'netilmicin sulfate, paromomycin sulfate, streptomycin sulfate, tobramycin'· .sulfate, miconazole hydrochloride, amanfadine hydrochloride, amantadine sulfate,· triclosan, octopirox, parachlorometa xylenol, nystatin, tolnaftate 20 ’ and clotrimazole and mixtures thereof.

Non-limiting , examples of anti-oxidants that are usable in the context of the present invention include.ascorbic acid (vitamin C) and its salts, ascorbyl esters of fatty acids, -ascorbic apid derivatives (e.g., magnesium ascorbyl phosphate, sodium .ascorbyl phosphate, ascorbyl sorbate), tocopherol (vitamin E), tocopherol sorbate, 25 tocopherol· acetate, other esters of tocopherol, butylated hydroxy benzoic acids and .· their salts, 6-hydroxy-2,5,738-tetramethylcbroman-2-carboxylic acid (commercially available under the hade name TroloxR), gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, lipoic acid, amines (e.g;,.· .N,N-diethylhy&lt;boxylamine, amino-guanidine), sulfhydryl . 30· . compounds (e.g., .giutathione), dihydroxy fumaric acid and its salts, lycine pidolate,· arginine pilolate, .nordihydroguaiaretic ' acid, bioflavonoids, curcumin, lysine, ' methionine, proline, superoxide dismufase, silymarin, tea extracts, grape skin/seed extracts, melanin, and rosemary extracts. WO 2005/069735 PCT/IL2005/000084 35

Non-limiting examples of chemotherapeutic agents usable in context of the present invention include daunorubicin, doxorubicin, idarubicin, amrubicin, . pirarubicin, epirubicin, mitoxantrone, etoposide, teniposide, vinblastine, vincristine, mitomycin C, 5-FU, pacbtaxel, docetaxel, actinomycin D, colchicine, topotecan, 5 irinotecan, gemcitabine cyclosporin, verapamil, valspodor, probenecid, MK571, GF120918,/LY3.35979, biricodar, terfenadine, quinidine, pervilleine A and XR9576.

Non-lindtiig · examples of antidepressants usable in context of the present invention include, norepinephrine-reuptake inhibitors ("NRIs"), selective-serotonin-reuptake-inhibitors (SSRIs), monoamine-oxidase inhibitors (MAOIs), serotonin-and- 10 noradrenaline-reuptake inhibitors ("SNFIs), corticotropin-releasing factor (CRF) antagonists, α-adrenoreceptor antagonists, NK1-receptor antagonists, 5-HTiA-receptor agonist, antagonists, and.partial agonists and atypical antidepressants, as well as norepinephrine-reuptake inhibitors · such as, but are not limited to amitriptyline, desmethylamitriptyline, clomipramine, doxepin, imipramine, imipramine-oxide, 15 trimipramine;. adinazolam, amiltriptylinoxide, amoxapine, desipramine, maprotiline, . nortriptyline, 'protriptyline, amineptine, butriptyline, demexiptiline, dibenzepin, dimetacrine,. dothiepih, fluacizine, iprindole, lofepramine, melitracen, metapramine, norclohpramine, 'noxiptilin, opipjramol, perlapine,. pizotyline, propizepine, quinupramme, rehoxetine, tianeptine, and serotonin-reuptake inhibitors such as, hut 20 are not limited .to, bmedaline, m-chloropiperzine, citalopram, duloxetine, etoperidone, femoxetine, '.fluoxetine, fluvoxamine, indalpine, indeloxazine, milnacipran, nefazodonej oxaflazone, paroxetine, prolintane, ritanserin, sertraline, tandospirone, venlafaxine and zimeldine. •Exemplary anti-dandruff ingredients usable in context of the present invention ' 25 include, without limitation, zinc pyrithione, shale oil and derivatives thereof such as sulfonated shale oil, selenium sulfide, sulfur; salicylic acid, coal tar, povidone-iodine, imidazoles such as ketoconazole, dichlorophenyl imidazolodioxalan, clotrimazole, itraconazole, miconazole, climbazole, tioconazole, sulconazole, butoconazole, fluconazole, miconazolenitrite and any possible stereo isomers and derivatives thereof 30 such as anthralin,· piroctone olamine (Octopirox), selenium sulfide, and ciclopirox olamine, and mbdures thereof. "Non-limiting examples of vitamins, usable in context of the present invention · . include vitamin A and its analogs and derivatives: retinol, retinal, retinyl palmitate, WO 2005/069735 PCT/IL2005/000084 36 retinoic' acid,/tretinoin, iso-tretinoin (known collectively as retinoids), vitamin E (tocopherol and its derivatives), vitamin C (L-ascorbic acid and its esters and other derivatives), vitamin B3 (niacinamide and its derivatives), alpha hydroxy acids (such as glycolic acid, lactic acid, tartaric acid, malic acid, citric acid, etc.) and beta hydroxy 5 acids (such as' salicylic acid and the like). ' Non-limiting examples of dermatological active ingredients usable in context of the present invention include jojoba oil and aromatic oils such as methyl salicylate, Wintergreen,' peppermint oil, bay oil, eucalyptus oil and citrus oils, as well as ammonium phetiolsulfonate, bismuth subgallate, zinc phenolsulfonate and zinc 10 salicylate. Non-limiting examples of antifungal agents .include miconazole, clotrimazole, butoconazole, fenticonasole, tioconazole, terconazole, sulconazole, . fluconazole, . haloprogin, ketonazole, ketoconazole, oxinazole, econazole, itraconazole, terbinafine, nystatin and griseofulvin.

Non-limiting examples of antihistamines usable in context of the present' 15 invention include, chlorpheniramine, brompheniramine, dexchlorphemramine, tripolidine, clemastine, diphenhydramine, promethazine, piperazines, piperidines, astemizole, loratadine' and terfenadine.

Suitable hormones for use in the context of the present invention include, for example,· andiogenic/compounds and progestin compounds. • 20 . · Representative · examples of androgenic compounds include, without limitation, methyltestosterone, androsterone, androsterone- acetate, androsterone-propionate, androsterone benzoate, androsteronediol, androsteronediol-3-acetate, androsteronediol-17-acetate, androsteronediol 3-17-diacetate, androsteronediol-17-benzoate, aridrosteronedione, androstenedione, androstenediol, 25 dehydroepiandrosterone, sodium dehydroepiandrosterone sulfate, dromostanolone, dromostanolone propionate, ethylestrenol, fluoxymesterone, nandrolone' phenpropionate, nandrolone decanoate, nandrolone furylpropionate, nandrolone cyclohexane-propionate, nandrolone benzoate, nandrolone cyclohexanecarboxylate,. androsteronediol-3-;acetate-l~7-benzoate, oxandrolone, oxymetholone, stanozolol, 30 testosterone, testosterone decanoate, 4-dihydrotestosterone, 5a-dihydrotestosterone, testolactone, 17q-methyl-19-nortestosterone and pharmaceutically acceptable esters and saltsthereof, and combinations of any of the foregoing. WO 2005/069735 PCT/IL2005/000084 37

Representative examples of progestin compounds include, without limitation, desogestrel, dydrogesterone, ethynodiol diacetate, medroxyprogesterone, levonorgestrel, medroxyprogesterone acetate, hydroxyprogesterone caproate, norethindrone, norethindrohe acetate, norethynodxel, allylestrenol, 19-nortestosterone, 5 lynoestrenol, ..quingestano'l acetate, medrogestone, norgestrienone, dimethisterone, ' ethisterone, eyproterone acetate, chlormadinone acetate, megestrol acetate, norgestimate,.norgestrel, desogrestrel, trimegestone, gestodene, nomegestrol acetate, progesterone, 5a-pregnan-3p,20a-diol sulfate, 5a-pregnan-3p,20p-diol sulfate, 5a-pregnan-3 β-οΙ-20-one, 16,5 a-pregnen-3 β-οΙ-20-one, 4-pregnen-20 β-ο1-3 -one-20- 10 sulfate, acetoxypregnenolone, anagestone acetate, eyproterone, dihydrogesterone, flurogestone acetate, gestadene, hydroxyprogesterone acetate, hydroxymethylprogesterone, hydroxymethyl progesterone acetate, 3-ketodesogestrel, megestrol, melengestrol acetate, norethisterone and mixtures thereof.

In addition to- the above, the treatment of an HPV-caused ailment according to 15 the present invention may be combined with other treatment methods known in the art (i.e., combination therapy). Thus, the method according to this aspect of the present invention may further involve additional treatment by any of the methods described above for treating HPV infections. The tellurium-containing compounds described above can thus be, for example, co-administered (simultaneously or separately) with •20 additional agents for treating HP Vs infections such as, for example, salicylic acid, .5-fluoruracil and the · like. Alternatively, the method described above can be accompanied by. any of the physical treatment methods described above (e.g., laser therapy, NO therapy and the like).

In any of the different embodiments of the method according to this aspect of 25 the present invention, the tellurium-containing compounds described herein can be provided to a subject either per se, or as part of a pharmaceutical composition where it is mixed with a pharmaceutically acceptable carrier.

Hence,· according to another aspect of ihe present invention there is provided a pharmaceutical composition, which comprises'a tellurium-containing compound as 30 described herein and a· pharmaceutically acceptable carrier.

As. used herein a "pharmaceutical composition" refers to a preparation of one or more of ihe active ingredients described herein with other chemical components such as physiologically suitable carriers , and excipients. The purpose of a WO 2005/069735 PCT/IL2005/000084 38 . pharmaceutical composition is to facilitate administration of a compound to the subject treated:

Hereinafter, the phrases "physiologically acceptable carrier" and "pharmaceutically, acceptable carrier" which may be interchangeably used refer to a 5 carrier or a diluent that.does.not cause significant irritation to the subject and does not abrogate the biological activity and properties of the administered compound.

Herein· the term "excipient" refers to an inert substance added to a pharmaceutical'composition to further facilitate administration of an active ingredient. Examples, without· limitation, of excipients include calcium carbonate, calcium 10 phosphate, various sugars and types .of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.

Techniques' for formulation .and administration of drugs may be found in "Remington’s Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest . edition, which is incorporated herein by reference. 15 As described above, suitable routes of systemic administration may, for example, include, oral, rectal, transmucosal, transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary .injections as well as intrathecal;, direct, .intraventricular, intravenous, inrtaperitoneal, intranasal, or intraocular injections. 20 Alternately, one may administer a. preparation in a local rather than systemic manner, for example, via injection of the preparation directly into a specific region of a patient's body..

Pharmaceutical compositions of the present, invention may he manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, 25 granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the present invention may he formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing 30 of the active.ingredients into preparations which, can he used pharmaceutically.

Proper formulation is dependent upon the route of administration chosen. WO 2005/069735 PCT/IL2005/000084 39

For injection, the active ingredients of the-invention may be formulated in aqueous solutions, .preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer.

For transmucosal administration, penetrants appropriate to the barrier to be 5 permeated are used· in tbe formulation. Such penetrants are generally known in the art.

For. oral administration, the compounds can be formulated readily by combining the active · compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be 10 formulated as. tablets,' pills,, dragees, capsules, liquids,' gels, syrups, slurries, suspensions,, and; the like, for oral ingestion by a patient. Pharmacological preparations for oral·use can be made using a solid excipient, optionally grinding tbe · resulting, mixture, .and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in 15 particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as] for example, maize starch, wheat starch, rice' starch, potato starch,, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carbomethylceUulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, 20 . such as cross-linked polyvinyl pyrrobdone, agar, or alginic acid or a salt thereof such as sodium alginate.

Dragee cores’ are provided with suitable coatings. For this purpose, concentrated sugar.;'solutions may be used which may optionally, contain gum arabic, • talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, 25 lacquer solutions and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may'be added to the tablets or dragee coatings for identification or to ' characterize .different combinations of active compound doses.

Pharmaceutical compositions, which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a 30 plasticizer,· such as glycerol .or sorbitol. The push-fit capsules may contain the active ’ ingredients in' admixture'· with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft .'capsules, the .active ingredients may be dissolved or suspended in suitable bquids, WO 2005/069735 PCT/IL2005/000084 40 such as fatty oils,' liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be .added. All formulations for oral administration should be in dosages suitable for·the chosen route of administration.

For buccal administration, the compositions may take the form of tablets or 5 lozenges formulated in conventional manner.

For adininistration by nasal inhalation, the active ingredients for use according to the present, invention are conveniently delivered in the form of an aerosol spray presentation from .a pressurized pack or a nebulizer with the use of a suitable propellant, e.g:, dichlorodifluoromethane, trichlorofluoromethane, dichloro- 10 tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage .unit may he'determined by providing a valve to deliver a metered amount. Capsules and cartridges pf; .e.g., gelatin for use in a dispenser may he formulated containing a powder .mix.ofthe compound and a suitable powder base such as lactose or starch. .The preparations described herein may be formulated for parenteral 15 administration, e.g., by bolus injection or continuous infusion. Formulations for injection'may be· presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous , vehicles, and may contain .formulatory agents such as suspending, stabilizing and/or dispersing agents. 20 Pharmaceutical compositions for parenteral administration include aqueous ·. solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty , acids esters such as ethyl oleate, triglycerides or liposomes. 25 ' Aqueous, injection suspensions may contain substances, which increase the viscosity of the suspension, -such as Sodium carboxymethyl cellulose, sorbitol or dextran. ' .Optionally, the suspension may also contain suitable stabilizers- or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions. 30. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use. WO 2005/069735 PCT/IL2005/000084 41 .The.-preparation of the present invention may also be formulated in- rectal compositions such..as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoabutter or other glycerides.

Pharmaceutical compositions suitable for use in context of the present 5 invention include compositions wherein the active ingredients are contained .in an amount effective to achieve the intended purpose. More specifically, a therapeutically -effective amount means an amount of active ingredients effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.

Determination of a therapeutically effective amount is well within the 10- capability of those skilled in the art. .

For . any preparation used in the methods of the invention, the therapeutically effective-amount'or dose can be estimated initially from in vitro assays. For example, ·· a dose can bejformhlated in animal models and such information-can be used to more accurately determine useful doses in· humans. ,15 Toxicity and therapeutic efficacy· of the active ingredients described herein can be determined by. standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies· can he used in formulating a range- of dosage for use in human. The dosage, may vary depending upon the dosage form employed and the route of 20 administration utilized· The exact formulation, route of administration and dosage can be chosen-by the'individual physician in view of the patient's condition. [See-e.g., Fingl, et al., (1975) "The Pharmacological Basis of Therapeutics", Ch. 1 p.l], · · Depending oh the severity and responsiveness of the condition to be treated, dosing can.be: of a single or a plurality of administrations, with course of treatment 25 lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved. - . The 'amduhf of a composition to be administered will, of course, be dependent '' • on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc. 30 Compositions including the preparation of the present invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate ' container,· and labeled for treatment of an indicated condition. WO 2005/069735 PCT/IL2005/000084 42

Compositions^ of the present invention may, if desired, be presented in a pack or dispenser device, such as ah FDA approved kit, which may contain one or more . unit dosage· forms containing the active ingredient The pack may, for example, comprise metal· or plastic foil, such as a blister pack. The pack or dispenser device 5 may be accompanied by instructions for administration. The pack or dispenser may • also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human of. veterinary' administration. Such notice, for example, may be of labeling 10 approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert.

As is further described above, a suitable route of administering the tellurium-containing compounds of the present invention include topical application. ' Hence/ in a preferred embodiment of the present invention, tiie pharmaceutical ' 15 composition is formulated in a form suitable for topical application on the treated area.

As used herein, the phrase "topical application" describes application onto a biological surface, whereby the biological surface include, for example, a skin area (e.g., hands, forearms, elbows, legs, face, nails, anus and genital areas as described above) or a mucosal-membrane. 20 By selecting the appropriate carrier and optionally other ingredients that can . be included in the- composition, as is detailed hereinbelow, the compositions of the present invention may'be formulated into any form typically employed for topical application. Hence, the compositions of the present invention can be, for example, in .· a form of a cream, an ointment, a paste, a gel, a lotion, a milk, a suspension, an 25 aerosol, a spray, a foam, a shampoo, a hair conditioner, a serum, a swab, a pledget, a pad; a patch and a. soap'.

Ointments ace' semisolid preparations, typically based on petrolatum or petroleum derivatives. The specific ointment base to be usedis one that provides for optimum delivery for the active agent chosen for a given formulation, and, preferably, 30 provides.for other .desired characteristics as well (e.g., emolliency). As with other carriers or vehicles, an ointment base should be inert, stable, nonirritating and nonsensitizing. As.'explained in Remington: The Science and Practice of Pharmacy, 19 th Ed., Easton, Pa:: Mack Publishing Co. (1995), pp. 1399-1404, ointment bases WO 2005/069735 PCT/IL2005/000084 43 ' maybe grouped in. four classes: oleaginous bases; emulsifiable bases; emulsion bases; and water-soluble bases. Oleaginous ointment bases include, for example, vegetable oils, fats obtained from animals, and semisolid hydrocarbons obtained from petroleum. Emulsifiable ointment bases, also known as absorbent ointment bases, 5 contain little or no water and include, for example, hydroxystearin sulfate, anhydrous lanolin and hydrophilic petrolatum. Emulsion ointment bases are either water-in-oil (W/O) emulsions' or. oil-in-water (O/W) emulsions, and include, for example, cetyl alcohol, glyceryl monostearate, lanolin and stearic acid. Preferred water-soluble ointmentbases are prepared from polyethylene glycols of varying molecular weight. 10 Lotions are preparations that are to be applied to the skin surface without' friction. Lotions· are typically liquid or semiliquid preparations in which solid particles, inchidingthe active agent, are present in a water or alcohol base. Lotions are typically prefened for treating large body areas, due to the ease of applying a more fluid composition. Lotions are typically suspensions of solids, and oftentimes 15 comprise a liquid oily emulsion of the oil-in-water type. It is. generally necessary that the insoluble· matter in a lotion be finely divided. Lotions typically contain suspending agents to produce better dispersions as well as compounds useful for localizing and holding the active agent in contact with the skin, such as methylcellulose, sodium carboxymethyl-cellulose, and the like. 20 .Creams are· viscous liquids or semisolid emulsions, either oil-in-water or water-in-Oil. Cream bases are typically water-washable, and contain an oil phase, an emulsifier and an aqueous phase. The oil phase, also called the "internal" phase, is generally comprised, of petrolatum and/or a fatty alcohol such as cetyl or stearyl alcohol. The aqueous phase typically, although not necessarily, exceeds the oil phase 25 in volume; and generally contains a humectant. The emulsifier in a cream formulation is· generally a nonionic, anionic, cationic or amphoteric surfactant. Reference maybe made to Remington: The Science and Practice of Pharmacy, supra, for further information.

Pastes;are semisolid dosage forms in which the bioactive agent is suspended in- 30 a suitable base.· Depending on the nature of the base, pastes are divided between fatty pastes or those made from a single-phase aqueous gels. The base in a fatty paste is generally petrolatum, hydrophilic petrolatum- and the like. The pastes made from single-phase aqueous gels generally incorporate carboxymethylcellulose or the like as WO 2005/069735 PCT/IL2005/000084 44 a base. Additional reference maybe made to Remington: The Science and Practice of Pharmacy, forfurther information.

Gel. formulations are semisolid, suspension-type systems. Single-phase gels contain organic macromolecules distributed substantially uniformly throughout the 5 carrier liquid, which is typically aqueous, but also, preferably, contain an alcohol and, ' optionally, an oil; Preferred organic macromolecules, i.e., gelling agents, are crosslinked acrylic acid polymers such as the family of carbomer polymers, e.g., carboxypolyalkylenes that may be obtained, commercially under the trademark Carbopol™. Other types of preferred polymers in this context are hydrophilic 10 polymers such as polyethylene oxides, polyoxyethylene-polyoxypropylene •copolymers and polyvinylalcohol.; cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose. phthalate, and methyl cellulose; gums such as tragacanth and xanthan gum; sodium alginate; and gelatin. .In order to prepare a uniform gel, dispersing . 15 agents such as'· alcohol or glycerin can he added, or the gelling agent can be dispersed by trituration, mechanical mixing or stirring, or combinations thereof.

Sprays -generally provide the active agent in an aqueous and/or alcoholic solution which .can'be misted .onto the skin for delivery. Such sprays include those . formulated to provide for concentration of the active agent solution at the site of 20 administration following delivery, e.g., the spray solution can he primarily composed of alcohol or other like volatile liquid in which the active agent can be dissolved. Upon delivery to the skin, fhe carrier evaporates, leaving concentrated active agent at the site of administration. '

Foam compositions· are typically formulated in a single or . multiple phase 25 liquid form and housed in.a suitable container, optionally together with a propellant which facilitates.. the. expulsion of the composition from the container, thus transforming it into; a.foam upon application. Other foam forming techniques include, . . for example tire “Bag-in-a-can” formulation technique. Compositions thus formulated typically contain.· a low-boiling hydrocarbon, e.g., isopropane. Application and 30 agitatiori of such'Va composition at .the body temperature cause the isopropane to vaporize .and generate the foam, in a manner similar, to a pressurized aerosol foaming • system. Foams cab be water-based of hydroalcoholic, hut are typically formulated .· with high alcohol content which, upon application to the skin of a user, quickly WO 2005/069735 PCT/IL2005/000084 45' evaporates, .driving the active ingredient through the upper skin layers to the site of treatment.

Skin patches typically comprise a backing, to which a reservoir containing the active agent is attached. The reservoir can be, for example, a pad in which the active 5 agent or composition is dispersed or soaked, or a liquid reservoir, patches typically ' further include' a .'frontal water permeable adhesive, which adheres and secures the device to the treated region.· Silicone rubbers with· self-adhesiveness can alternatively be used. In .both, cases, a protective permeable layer can be used to protect the adhesive side of the patch prior to its use. Skin patches may further comprise a 10 removable cover, which serves for protecting it upon storage.

Examples · of pharmaceutically acceptable carriers that are suitable for pharmaceutical compositions for topical applications include carrier materials that are well-known'for use in the. cosmetic and medical arts as bases for e.g., emulsions, creams, aqueous solutions, oils, ointments, pastes, gels, lotions, milks, foams, 15 suspensions, aerosols-and the like, depending on the final form of the composition.

Representative examples of suitable carriers according to the present invention therefore include, without limitation, water, liquid alcohols, liquid glycols, liquid polyalkylene glycols,., liquid esters, liquid amides, Equid protein hydrolysates, liquid . alkylated protein.. hydrolysates, liquid lanolin and lanolin derivatives, and like 20 materials commonly employed in cosmetic and medicinal compositions.

Other suitable carriers according to the present invention include, without limitation, alcohols, such as, forexample, monohydric and polyhydric alcohols, e.g., ethanol, isopropanol,· glycerol, sorbitol, 2-methoxyethanol, diethyleneglycol, ethylene glycol, hexyleneglycol, mannitol, and propylene glycol; ethers such as diethyl or . 25 dipropyl ether; polyethylene glycols and methoxypolyoxyethylenes (carbowaxes' having molecular weight ranging from 200 to 20,000); polyoxyethylene glycerols, polyoxyethylene sorbitols, stearoyl diacetin, and the like.

When,the. pharmaceutical composition according to the present invention is formulated for. topical application, the concentration of the tellurium-containing 30 compound· preferably· ranges from about 0.01 weight percent and about 50 weight •percents fiomythe total weight of the composition.

Thus,'depending oh the condition being treated and the composition form, the concentration Of the tellurium-containing compound can he, for example, 0.01 weight WO 2005/069735 PCT/IL2005/000084 46 percent, 0.05 weight percent, 0.1 weight percent, 0.5 weight percent, 1 weight percent, 2 weight percents, 3 weight percents, 4 weight percents or 5 weight percents. Preferably, the concentration of the tellnrium-containing compound is 5 weight percents and higher and thus can be, for example, 5 weight percents, 6 weight 5 percents, 7 weight percents, 8 weight percents, 9 weight percents or 10 weight percents. 10 weight'percents and higher and therefore can he, for example, 11 weight percents, 12 weight/percents, 13 weight percents, 14 weight percents, 15 weight percents, 16 weight, percents, 17 weight percents, 18 weight percents, .19 weight - percents, 20 weight percents, 21 weight percents, 22 weight percents, 23 weight • 10 percents, 24 weight percents and up to 25 weight, percents of the total weight of the composition. Alternatively, the concentration of the tellurium-containing compound is higher than 25 weight percents and can he up to 50 weight percents of the total weight of the composition.

Each of the pharmaceutical compositions described herein may further 15 comprise, according to an embodiment of the present invention an additional active agent, as described'hereinabove.

Each of the pharmaceutical compositions described herein can optionally further comprise· af.variety of components that are suitable for providing the compositions with additional usage benefits. Such conventional optional components 20 are well known to'those skilled ih the art and are referred to herein as “ingredients”. Some non-limiting representative examples of these ingredients include humectants, ’ deodorants, antiperspirants, sun screening agents, sunless tanning agents, hair . conditioning agents, 'pH adjusting agents, chelating agents, preservatives,· emulsifiers, occlusive agents,, emollients, thickeners, solubilizing agents, penetration enhancers, . 25 anti-irritants, colorants, propellants (as described above) and surfactants.

Thus, for example, the compositions of the present invention can comprise humectants or moisturiring agents. Representative examples of humectants that are usable in; this context of the present invention include, without limitation, guanidine, glycolic, acid arid glycolate-salts (e.g. ammonium slat and quaternary alkyl ammonium 30 salt), aloe vera.in any of its variety of forms (e.g., aloe vera gel), allantoin, urazole, • polyhydroxy .alcohols such as sorbitol, glycerol, hexanetriol, propylene glycol, butylene glycol,'.hexylene glycol and the like, polyethylene glycols, sugars and starches, sugar arid /starch derivatives (e.g., alkoxylated glucose), hyaluronic acid,. WO 2005/069735 PCT/IL2005/000084 47 lactamide monoethanolamine, acetamide monoethanolamine and any combination thereof.

The compositions of the present invention can further comprise a pH adjusting agent. The addition of a pH adjusting agent is particularly preferred when the . 5 · compositions are applied topically on the skin or in the genital areas. The pH of these treated areas is typically lower than 6.0. Hence, it is preferable for the compositions of the present - invention to have a pH value of between about 4 and about 7, preferably between about 4 and about 6, so as to avoid irritations to the skin or induction of imbalance of the bacteria population if the genital areas. Suitable pH io adjusting agents include, for example, one or more of adipic acids, glycines, citric . acids, calciund hydroxides, magnesium aluminometasilicates, buffers or any combinations thereof.

Representative examples of deodorant agents that axe usable in ihe context of the present invention include, without limitation, quaternary ammonium compounds • .15 such as cetyl-trimethylammonium bromide, cetyl pyridinium chloride, benzethonium • chloride,· diisobiityl -phenoxy ethoxy ethyl. dimethyl benzyl ammonium chloride, sodium Nrlapfyl sarcosine, sodium N-pahnlthyl sarcosine, lauroyl sarcosine, N-myristoyl glycine,· potassium N-lauryl sarcosine, stearyl, trimethyl ammonium chloride, sodium aluminum chlorohydroxy· lactate, tricetylmethyl ammonium 20 . chloride, 2,4,4-trichloro-2'-hydroxy diphenyl ether, diaminoalkyl amides such as L-. lysine hexadeqyl amide, heavy, metal salts of citrate, salicylate, and · piroctose, especially zinc-salts·, and acids thereof, heavy metal salts of pyrithione, especially zinc •pyrithione and.zmc.phenolsulfate. Other deodorant agents include, without limitation, odor absorbing-materials such as carbonate and bicarbonate salts, e.g. as the alkali 25 metal carbonates and bicarbonates, ammonium and tetraalkylammonium carbonates and bicarbonates,-especially the sodium and potassium salts, or any combination of the above.

Antiperspirant agents can be incorporated in the compositions of the present • invention either in a solubilized or a particulate form - and include, for example, 30 aluminum or zirconium astringent salts or complexes.

Representative examples of sun screening agents usable-in context of the present· invention J include, without limitation, -p-aminobenzoic acid, salts and . derivatives thereof (ethyl, isobutyl, glyceryl · esters; p-dimethylaminobenzoic acid); WO 2005/069735 . PCT/EL2005/000084 48 anthranilates (i.e., o-amino-benzoates; methyl, menthyl, phenyl, benzyl, phenylethyl, linalyl, teipinyl, and cyclohexenyl esters); salicylates (amyl, phenyl, octyl, benzyl, menthyl, glyceryl, and di-pro-pyleneglycol esters); cinnamic acid derivatives (menthyl and benzyl esters, a-phenyl cinnamonitrile; butyl cinnamoyl pyruvate); 5 dihydroxycinnamic acid derivatives (umbelliferone, methylumbelliferone, • methylaceto-umbelhferone); trihydroxy-cinnamic acid derivatives (esculetin, methylesculetin, daphnetin, and the glucosides; esculin and daphnin); hydrocarbons (diphenylbutadiene, stilbene); dibenzalacetone and benzalacetophenone; naphtholsnlfonates (sodium salts of 2-naphthol-3,6-disulfonic and of 2-naphthol-6,8- 10 disulfonic acids); di-hydroxynaphthoic acid and its salts; o- and p-hydroxybiphenyldisulfonates; coumarin derivatives (7-hydroxy, 7-methyl, 3-phenyl); diazoles (2-acetyk3-bromoindazole, phenyl benzoxazole, methyl naphthoxazole, • various aryl benzothiazoles); quinine salts (bisulfate, sulfate, chloride, oleate, and tannate); quinoline derivatives (8-hydroxyquinoline salts, 2-phenylquinoline); 15 hydroxy- or methoxy-substituted benzophenones; uric and violuric acids; tannic acid and its derivatives (e.g., hexaethylether); (butyl carbotol) (6-propyl piperonyl) ether; hydroquinone; benzophenones (oxybenzene, sulisobenzone, dioxybenzone, benzoresorcinol, 2,2',4,4'-tetrahydroxybenzophenone, 2,2'-dihydroxy-4,4'-dimethoxybenzophenone, octabenzone; 4-isopropyldibenzoylmethane; •20 butylmethoxydibenzoylmetharie; etocrylene; octocrylene; [3-(4'-methylbenzylidene boman-2-one) and 4-isopropyl-di-benzoylmethane, and any combination thereof.

Representative examples of sunless tanning agents usable in . context of the present invention include, without limitation, dihydroxyacetone, glyceraldehyde, indoles and their derivatives. The sunless tanning agents can .be used in combination '25 ' with the sunscreen agents.

The chelating agents are optionally added to the compositions of the present invention so as to enhance the preservative or preservative system. Preferred chelating agents, are mild agents, such as, for example, ethylenediaminetetraacetic acid (EDTA), EDTAderivatives, or any combination thereof. 30 Suitable preservatives that can be used in the context of the present

composition include, without limitation, one or more alkanols, disodium EDTA (ethylenediamihe - . tetraacetate), EDTA salts, EDTA fatty acid conjugates, ' isothiazolinone, parabens such as methylparaben and propylparaben; propylene WO 2005/069735 • PCT/IL2005/000084 •49 glycols, sorbates, urea derivatives such as diazolindinyl urea, or any combinations thereof. -

Suitable emulsifiers that can be used in the context of the present invention include, for example, one or more sorbitans, alkoxylated fatty alcohols, 5 alkylpolyglycosides, soaps, alkyl sulfates, monoalkyl and dialkyl phosphates, alkyl sulphonates, acyl isothionates, or any combinations thereof.

Suitable occlusive agents that can be used in the context of tbe present invention include, for-example, petrolatum, mineral oil, beeswax, silicone oil, lanolin and oil-soluble lanolin derivatives, saturated and unsaturated fatty alcohols such as 10 bebenyl alcohol,'hydrocarbons such as squalane, and various animal and vegetable oils such as almond 'oil, peanut oil, wheat germ oil, linseed oil, jojoba oil, oil of apricot pits, Walnuts, palm nuts, pistachio nuts, sesame seeds, rapeseed, cade oil, com oil, peach pit oil, poppyseed oil, pine oil, castor oil, soybean oil, avocado oil, safflower oil, coconut oil, hazelnut oil, olive oil, grape seed oil and sunflower seed 15 oil.

Suitable emollients,that can be used in tbe context of the present invention include, for example, dodecane, squalane, cholesterol, isohexadecane, isononyl isononanoate, PPG. Ethers, petrolatum, lanolin, safflower oil, castor oil, coconut oil, cottonseed oil, palm kernel oil, palm oil, peanut oil, soybean oil, polyol carboxybc 20 acid esters, derivatives, thereof and mixtures thereof.

Suitable thickeners that can be used in the context of the present invention include, for example, non-ionic water-soluble polymers such as hydroxyethylcellulose (commercially available under the Trademark Natrosol.RTM. 250 or 350), cationic .. water-soluble polymers such as Polyquat 37 (commercially available under the 25 Trademark Synthal'en.RTM. CN), fatty alcohols, fatty acids and their alkab salts and · . mixtures thereof. '

Representative examples of solubilizing agents that are usable in. this context of the present, invention include, without , limitation, complex-forming solubilizers . such as citric .acid,· ethylenediamine-tetraacetate, sodium meta-phosphate, succinic '30 . acid, urea, cyclodextrin, polyvinylpyrrolidone, diethylammonium-ortho-benzoate, and micelle-forming solubilizers such as TWEENS and spans, e.g., TWEEN 80. Other solubilizers that are .usable for the compositions of the present invention are, for example, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene n-alkyl ethers, n- WO 2005/069735 . PCT/EL2005/000084 50 alkyl amine n-oxides, poloxamers, organic solvents, phospholipids and cyclodextrines.

Suitable penetration enhancers usable in context of the present invention include, but are not limited to, dimethylsulfoxide (DMSO), dimethyl formamide 5 (DMF), allantoin^ urazole, Ν,Ν-dimethylacetamide (DMA), decylmethylsulfoxide (Cio MSO), polyethylene glycol monolaurate (PEGML), propylene glycol (PG), propylene glycol monolaurate (PGML), glycerol monolaurate (GML), lecithin, the 1-substituted azapycloheptan-2-ones, particularly l-n-dodecylcyclazacycloheptan-2-one (available under the trademark AzoneR™ from Whitby Research Ihcoiporated, 10 Richmond, Va.),· alcohols, and the like. The .'permeation enhancer may also he a vegetable oil. Such oils include, for example, safflower oil, cottonseed oil and com oil. .

Suitable anti-irritants that can be used in the context of the present invention •include, for- exainple, steroidal and non steroidal· anti-inflammatory agents· or other 15 materials such.as aloe vera, chamomile, alpha-bisabolol, cola nitida extract, green tea extract, tea tree oil/ licoric extract, allantoin, caffeine or other xanthines, glycyrrhizic acid and its derivatives.

The compositions of the present invention may he packed or presented in any convenient way. For example, they may he packed in a tube, a bottle, or a pressurized 20 container, using techniques well known to those skilled in the art and as set forth in reference works such as Remington's Pharmaceutical Science 15th Ed. It is preferred that the packaging: is done in such a way so as to minimize contact of the unused • compositions with the environment, in order to minimize contamination of the compositions before and after the container is opened. 25 The compositions are preferably identified in print, in or on' the' packaging material, for use in the treatment an ailment caused by HPV, as described hereinabove.

Additional, objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following 30 examples, which are not intended to be limiting. Additionally, each of the Various . ejfrbodiments and aspects· of the present invention as delineated hereinabove and as . claimed in the claims section below finds experimental support in the following examples. ' . WO 2005/069735 . PCT/IL2005/000084 51

EXAMPLES

Reference is now made to the following examples, which together with the ' above descriptions, illustrate the invention in a non limiting fashion. 5 EXAMPLE 1

Preparation of compositions containing tellurium compounds

Compositions for topical or systemic application, which contain one or more of the tellurium compounds described herein and optionally pharmaceutically acceptable carriers and excipients, are formulated as creams, lotions, ointments, gels, 10 solutions, foams, . mousses and the like (as is detailed hereinabove), using ’ conventional methods (see, for example, (see, .for example, Harry's Cosmeticology,

Seventh Edition, Edited by JB. Wilkinson and RJ Moore, Longmann Scientific '&amp;amp; Technical, 19S2, .Chapter 13 "The Manufacture of Cosmetics" pages. 757-799; and “Remington’s .Pharmaceutical Sciences,” Mack Publishing Co.', Easton, PA, latest 15 edition). . /·

Exemplary - compositions for topical application according to the present invention were prepared in the form of a cream as follows:

Preparation.of Composition 1:

Forty (40) grams' of a powdered ammonium trichloro(dioxoefhylene-20 O,O')tellurate (AS-101, manufactured under GLP by IMI (TAMI) Institute for Research &amp;amp; Development -Ltd., Israel) were, dissolved in 100 ml dimethyl sulfoxide, so as to make a 40 % w/w solution. The solution was then combined with an equal weight of petrolatum, U.S;P. (e.g., Intensive Vaseline cream) so as to make a cream containing about 17 % - 20 % by weight of the tellurate. 25 Preparation of Composition 2:

Composition i. was-prepared as described above for Composition 1,· with the addition of 6 % by weight of salicylic acid.

Another exemplary' composition . according to the present invention was prepared in theform of a solution, which can be administered as drops, as follows: 30 Preparation of Composition 3: .10 grams of. ammonium trichloro(dioxoethylene-0,0')tellurate (AS-101) were dissolved in 90 grams DMSO to thereby form a 10 % solution of AS-101. WO 2005/069735 PCT/BL2005/000084 • 52 EXAMPLE 2

Treatment of condyloma acuminatum with a tellurium composition A human patient with condyloma acuminatum in the perianal region was treated with Composition 1 (described in Example 1 hereinabove) by topically 5 applying the composition twice daily on and around the affected area for a period of about 4 weeks..

Following.a.few days of treatment the lesion changed color from pink to grey-black and following about -4 to 5 weeks, the lesion substantially sloughed off without leaving any scarring.. Figures 1-5 present images of the treated area, which show the 10 effect of the therapy .-.on the condyloma at bi-weekly intervals during the period of treatment. EXAMPLE 3

Treatment of verruca with a tellurium composition 15 A human-.patient with a veirucca lesion on the hand was treated with

Composition 3 described in Example 1 hereinabove. The formulation was applied on and around the affected area twice daily for a period of about 10 weeks. Figures 6-8 present images showing the progress of treatment at bi-weekly intervals. As is shown in, for example, Figure 8, at the end of the period of treatment, the wart substantially 20 sloughed off leaving no scar on the treated area. EXAMPLE4 ' Treatment of verruca with a tellurium composition A human patient with’multiple verrucca lesions on the hand was treated with 25 Composition 3 described in Example 1 hereinabove. The formulation was applied twice daily for .a period of about '4 weeks. Figures 9-11 present images showing the progress of treatment· at biweekly intervals. As is shown in, for example, Figure 11, . at the end of the period of treatment, the wart substantially sloughed off leaving no scar on the treated?area. 30 WO 2005/069735 PCT/IL2005/000084 53 EXAMPLE 5

Treatment of condyloma acuminatum with a tellurium composition A 26-years .old female with condyloma acuminata in the genital region was treated with Composition 1 (described in Example 1 hereinabove) by topically 5 applying the Composition twice daily on and around the affected area for a period of about 4 weeks..

Figures 12-14 present images of the treated area, demonstrating the effect of the therapy on the condyloma at bi-weekly intervals during the period of treatment. As is shown in, for example, Figures 14a-b, at the end of the period of treatment, the 10 wart substantially sloughed off, leaving no scar on the treated area. EXAMPLE 6

Treatment of condyloma acuminatum with a tellurium composition A· 25-years old female with condyloma acuminata in the genital region was 15 treated with Composition 1 (described in Example 1 hereinabove) by topically applying the composition twice daily on and around the affected , area for a period of • about 4 weeks.

Figures.15-17 present images of the treated area, demonstrating the effect of the therapy on .the condyloma at bi-weekly intervals during the. period of treatment. 20 As is shown in, for. example, Figure 17, at the end of the period of treatment, the wart substantially sloughed off, leaving no scar on the treated area. EXAMPLE 7

Treatment of condyloma acuminatum with a tellurium composition 25 · A 28-years old female with condyloma acuminata in the genital region was treated with .Composition 1 (described in Example 1 hereinabove) by topically applying the composition twice daily on and around the affected area for a period of about 2 weeks:·) · ·

Figure's.!8-19 present images of the treated area, before (Figure 18) .and after 30· . (Figure 19) treatment with a composition according to .the present invention, demonstrating the .effect of the therapy on the condyloma, during the period of. treatment.. As' is shown in Figure 19, at the end of the period of treatment, the wart ' substantially slouched'off,· leaving no scar on the treated area. WO 2005/069735 PCT/DL2005/000084 54 EXAMPLE 8

Treatment of condyloma acuminatum with a tellurium composition A 29-years old male with condyloma acuminata in the anus was treated with

Composition 1. (described in Example 1 hereinabove) by topically applying the 5 composition twice.daily on and around the affected area for a period of about 8-9 weeks; • Figures -20-23 present images of the treated area, demonstrating the effect of the therapy on the condyloma after two' days (Figure 21) about 5 weeks (Figure 22) and about 8 weeks of therapy. As is shown in, for example, Figure 23, at the end of the period of treatment, the wart substantially sloughed off, leaving no scar on the • io treated area. EXAMPLE 9

Treatment of verruca vulgaris with a tellurium composition A i8-years old female with verruca vulgaris on both hands was treated with 15 Composition 2- (described in Example 1 hereinabove) by topically applying the composition twice daily on and around the affected area for a period of about 6-7 weeks.

Figures'24-26 present images of the treated area, demonstrating the effect of •.the. therapy on the verruca vulgaris after about 3 weeks (Figures 25 a-b) and about 6· weeks (Figures 2.6’ a-b) of treatment. 20 ' EXAMPLE 10

Treatment of condyloma acuminata with a tellurium composition A 28-years old female- with condyloma acuminata in the genital was. treated with Composition 1 (described in Example 1 hereinabove) by topically applying the 25 . composition.twice daily onand around the affected area for a period of about 8 weeks.

Figures 27a-.d present images of the treated area, which show the effect of .the therapy on tid&amp;amp; 'condyloma acuminata at about bi-weekly or tri-weekly intervals during ' the period of treatment WO 2005/069735 PCT/IL2005/000084 55 EXAMPLE!!

Treatment of condyloma acuminata with a tellurium composition A 35-years old. female with condyloma acuminata in the genital was treated with Composition 1 (described in Example 1 hereinabove) by topically applying the 5 composition twice daily on and around the affected area for a period of about 8-9 weeks. ' Figures- 28'a-.d present images of the treated .area, which show the'effect of the therapy on the condyloma acuminata at about bi-weeldy or tri-weekly intervals during the period of treatment. 10 EXAMPLE12

Treatment of condyloma acuminatum with a tellurium composition A 27-years old male with condyloma acuminata in the anus was treated with · Composition .1 (described in Example 1 hereinabove) by topically applying the composition twice daily on and around the affected area for a period of about .10 weeks. 15 Figures. 29a-e present images of ihe treated area, demonstrating the effect of . ’ the therapy on the condyloma after at about bi-weekly or tri-weekly intervals during the period of treatment. EXAMPLE 13 20 Treatment of condyloma acuminatum with a tellurium composition A 25-years old male with condyloma acuminata in the anus was treated with Composition '1 (described in Example 1 hereinabove) by topically applying the composition twice-daily on and around the affected area for a period of about 10 weeks.

Figures 30a-d present images of the treated area, demonstrating the effect of •25 . ' the therapy on the . condyloma after about 4 weeks' intervals during the period of · treatment. EXAMPLE 14.

Treatment of verruca vulgaris with a tellurium composition 30. (open use pilot study)

Protocol:

Twentyreight; patients (19 men and 9 women) aged 17-72 years (mean 26 ' years) were'enrolled in an open use pilot' study. All patients had typical verruca · WO 2005/069735 PCT/DL2005/000084 56 vulgaris of the hands. Eleven of them, had relatively new lesions (of less than 6 months) which had not been treated previously, while the other 17 had long-standing, heavily pre-treated (including liquid nitrogen, laser, salicylic acid, etc.) lesions.

Two patients' were immunosuppressed (post recent heart and bone marrow 5 transplants). . An.. additional patient had received chemotherapy a few months previously for'..lung'· carcinoma (complete remission during the protocol treatment period).arid another patient had surgery one month prior to the study for carcinoma of the thyroid. 1. All patients were examined by the protocol physicians, so as to evaluate the 10 ability of AS 101 toeradicate verruca vulgaris and the safety of the topical application. A 10 % solution of ammonium trichloro (dioxoethylene-O,O') tellurate (AS- 101) in DMSO (Composition 3 in Example 1 hereinabove) was applied on and around a single lesion twice daily, two drops in the morning and two drops at night for three weeks. Patients were examined once a week in the period of treatment and a bi- 15 weekly follow up was carried out for 3-12 weeks post treatment. In patients with multiple warts,.only one wart was selected for·treatment. A complete response was defined as the total disappearance of the wart; a major response was over 80 % reduction in the size and an overall response in those who had either a.complete response or a major response. 20 ' Results: ·

Twenty-three patients were available for evaluation at the end of the study. Five patients stopped treatment for unclear-reasons. After three weeks of treatment, a complete response was observed in 10 out of 23 (43 %) of the patients and a lesser response in 3 out of 23 (13 %). Seven of the patients who had a major response were 25 treated for another three weeks. At the end of the additional three weeks, one patient had a complete response while another showed further improvement.

Overall response (complete or major) was observed in 20 out of 23 patients ' (87.%) .after 3-6 weeks of treatment. The response rate was unrelated to the previous treatment and was the same for previously treated and untreated warts. 30 . No side effect's were observed besides the temporary (several days duration) black discoloration'around the wart, and sometimes sublingually, which was reported by some of the .patients in the study. Some patients experienced slight pain for a few WO 2005/069735 PCT/IL2005/000084 57 hours following the application. This pain was significantly less than the pain caused by the use of liquid hitrogen.in the cryosurgical removal of warts. EXAMPLE 15 5 Treatment of Condyloma Acuminata in females with a tellurium composition (open use pilot study)

Protocol:

Female patients aged 18 years and up were enrolled in an open use pilot study. 10 All patients had diagnosed HPV genital warts;

Patients were examined by the protocol physicians, so as to evaluate the ability of AS101 to. eradicate Condyloma Acuminata and the safety of the topical .application. A 20 % cream composition (Composition 1 described in Example 1 above) 15 was applied on arid' around the targeted area twice daily, and was maintained for at · least two hours before taking a shower. Patients were examined every other week during treatment and every two months for a six months post treatment period. A complete-response was defined as a reduction of 95-100 % in the size of the warts (averaged); a partial response was defined as a reduction of 70-94 % in the size 20 of the warts (averaged); and no response was defined as less than 70 % reduction in . the size of the warts'(averaged).

Results: .''·

This study-is still ongoing, and therefore conclusive data has not been established yet Preliminary results, however, obtained regarding the 21 patients who 25 ' completed the treatment indicate a complete cure in 18 patients (85.7 %), following a treatment period ranging between a minimum period of 14 days and a maximal period of 84 days (an average treatment period of 38 days), and no response in 1 patient (4.7 %). Two patients Were dropped out of the trial voluntarily. .Local, light to moderate anticipated side effects such as erythrema, itching, 30 slight bum and the like were observed in 9 of the 21 patients (42.8 %), whereby non- local adverse effects .such as allergic reaction or strong local hum were observed in 3 patients.(14.2.%).' · WO 2005/069735 PCT/DL2005/000084 58 EXAMPLE 16

Treatment of. Condyloma Acuminata in males with a tellurium composition (open use pilot study)

Protocol: . 5 Male patients 'aged 18 years and up were enrolled in an open use pilot study.

All patients had diagnosed HPV in the anus.

All patients were examined by the protocol physicians so as to evaluate the • ability- of AS 101 to eradicate Condyloma Acuminata and the safety of the topical application. .' .· . 10 A 20 % cream composition (Composition 1 described in Example 1 above), was applied on .’and around the targeted area twice daily. Patients were examined on a bi-weekly basis during treatment and every two months for a six months post treatment period. '. A complete response was defined as a reduction of 95-100 % in the size of the 15 · warts (averaged);· a. partial response was defined as a reduction of 70-94 % in the size of the warts (averaged); and no response was defined as less than 70 % reduction in the size of the warts (averaged).

Results:

Since 'the studies described above are still ongoing, conclusive data has not .20 been established .yet.·' Preliminary results, however, obtained regarding the 12 patients • who completed 'the7, treatment indicate a complete cure in 7 patients (53.8 %), follovring.a treatihent period ranging between a minimum period of 42 days and a maximal period of 105 days (an average treatment period of 67 days), and no response in 3 patients (25 · %).·, One patient dropped out of the trial voluntarily. 25 Local, light, to moderate anticipated side effects such as erythrema, itching, ·' slight hum and the. like were observed in 9 of the 12 patients (75 %), whereby non-local adverse effect^ such as allergic reaction, or strong local hum were observed in 2 • patients (16.6 %).· · 30 It is apfpre'eiated that certain features of the invention, which are, for clarity, described .in'.the ; context· of separate embodiments, may also- he provided in .combination in- a single embodiment Conversely, various features of the invention, WO 2005/069735· PCT/IL2005/000084 ; 59 which are, for brevity, described in the context of a single embodiment, may also be provided, separately'or in any suitable subcombination.

Although the invention has been .described in conjunction with specific 5 embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to'those skilled in the art. Accordingly, it is intended to· .embrace all such alternatives, modifications and variations that fall within' the spirit and broad scope of the appended claims. All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference 10 into the specification, to the same extent as if each individual publication, patent or patent apphcatibnwas specifically and individually indicated to be incorporated herein ' by reference. In addition, citation or identification of any reference in this application shall not be construed, as an admission that such reference is available as prior art to the present invention.